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ABSTRACT
Nicholas C. Gomez: Mechanisms of Ewing sarcoma development and therapeutic
resistance.
(Under the direction of Ian J. Davis.)
Many large scale consortia have begun to use high-throughput sequencing tech-
nologies to identify key mutations and pathways involved in the etiology of cancers.
Identification of specific mutations within tumors can also influence patient-directed
therapeutic decisions. Recent evidence implicates the insulin-like growth factor path-
way in development of Ewing Sarcoma, a highly malignant bone and soft tissue tumor
that primarily affects children and young adults. Despite promising results from pre-
clinical studies of therapies that target this pathway, early phase clinical trials have
shown that a significant fraction of patients do not benefit, suggesting that cellular
factors determine tumor sensitivity. All cases of Ewing sarcoma are characterized by
a translocation between EWSR1 and an ETS-family transcription factor where 85% of
the cases result in the EWSR1-FLI1 t(11;22)(q24:q12). This novel transcription factor
is retargeted to a subset of repetitive elements in a cell-type specific manner by a
previously unknown mechanism. In the chapters that follow, we describe the cellular
consequences of PTEN loss in Ewing sarcoma as well as a mechanism for EWSR1-
FLI1 retargeting. We demonstrate that Ewing sarcoma cells with PTEN loss exhibited
increased transformative properties, as well as reciprocal sensitivity to IGF-1R and
mTOR inhibition, therapies currently undergoing testing in clinical trials. In addition,
our studies also describe a novel chromatin environment of stem cells in which repet-
itive elements are enriched in accessible chromatin. Strikingly, a subset of accessible
repetitive elements in stem cells is associated with Ewing Sarcoma development.
Repetitive elements exhibiting the greatest FAIRE signal in stem cells, is associated
iii
with increased EWSR1-FLI1 binding, suggesting the chromatin environment of stem
cells is primed for oncogenesis. Taken together, these studies expand our knowledge
of Ewing sarcoma etiology and provide a potential mechanism for therapy resistance.
This work serves as the foundation for both expanded preclinical and clinical research
for future targeted therapies in Ewing sarcoma.
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CHAPTER 1
INTRODUCTION
Advances in sequencing technologies have led to many discoveries ranging from
the understanding of genome-wide regulatory elements such as enhancers [1] to the
associations of complex diseases with specific mutations and genomic loci [2][3]. The
human genome sequencing project was declared complete in 2003 and has served
as the foundation for genomics, a new era in the biological sciences. Advances in
sequencing technology have led to sequencing being coupled to previously known
biochemical techniques such as chromatin immunopreciptiation (ChIP) [4][5][6], DNa-
seI hypersensitivity (DNase) [7][8], Micrococcal nuclease digestion (MNase) [9], and
RNA isolation [10][11][12]. The field of genomics began to rapidly expand as high-
throughput sequencing allowed researchers to analyze information not just for a hand-
ful of loci, but now genome-wide, increasing exponentially the amount of available
information. The wealth of data gave rise to bioinformaticians who developed new
tools and algorithms to handle the massive datasets. Large multi-institutional con-
sortia, such as the Encyclopedia of DNA Elements (ENCODE) and the Epigenome
Roadmap, were created and tasked with identifying and understanding the functional
elements of normal and disease states of human cells [13][14]. These consortia have
directly led to creation of terabytes of publically available data that can be mined by
researchers all of the world to answer specific biological questions.
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1.1 Embryonic stem cells are derived from the Inner cell mass
Human embryonic stem cells (hESC) are derived from the inner cell mass of
the blastula. Post-fertilization, the zygote undergoes rapid cell division transitioning
through several stages before becoming the blastocyst around day five. The blas-
tocyst consists of two cellular grups an outer lining of trophoblasts and an inner cell
mass. The trophoblasts will eventually go on to form extra-embryonic tissues such as
the placenta, chorion, and umbilical cord, while the inner cell mass will form the entire
embryo. In 1981, a seminal discovery in stem cell research was made when the first
pluripotent cells were isolated from the mouse blastocyst [15][16]. 17 years later the
first human ESC (hESC) lines were established [17]. hESCs are unique in the ability
to be cultured indefinitely, while still retaining pluripotency: the ability to differentiate
into cell types from all three of the embryonic germ layers, endoderm, mesoderm, and
ectoderm [17](Figure 1.1). Using well defined chemicals and transcription factors, re-
searchers have been able to differentiate into neurons [18], cardiomyocytes[19][20],
and muscle [21] among others [22]. The ethical issues surrounding the study of
human development in-vivo have prevented advances in understanding of these pro-
cesses. With the establishment of hESC, these cell lines, and the accompanying abil-
ity to differentiate are excellent surrogates for the study of developmental processes
including chromatin changes.
1.2 Chromatin Organization
With completion of the human genome project, a new challenge developed - the
identification of functional elements in the genome. Of the 3.3 billion bases in the hu-
man genome, only 3% encode proteins. The remainder has commonly been referred
to as “junk” DNA [23]. Though non-coding, recent studies have began to show the
importance and functionality of these regions in evolution [24][25], transcription fac-
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tor binding[26][27], and disease risk [28]. Interestingly, nearly 50% of the noncoding
human genome, is comprised of repetitive elements [29][30], suggesting a potential
importance of the elements in human biology.
Human repetitive elements are often classified into two broad categories, short
tandem repeats (also known as microsatellites), represented by simple repeats, and
interspersed repeats represented by short and long interspersed nuclear elements
(SINEs and LINEs respectively). In addition to SINEs and LINEs, interspersed re-
peats also consist of long terminal repeats (LTR) and endogenous retroviruses (ERV).
These are referred to as retrotransposons, as they have acquired a mechanism to
copy and insert themselves into the genome through an RNA intermediate. Retro-
transposons have been demonstrated to be active a variety of adult tissues as well
as during embryonic development [31][32]. Repetitive elements are also able to in-
Fertilization
Blastocyst
Embryonic Stem Cells
Inner Cell Mass
Ectoderm
Brain, Skin
Mesoderm
Bone, Muscle
Endoderm
Lung, Liver
Figure 1.1: Post-fertilization rapid cell division occurs ultimately forming the blasto-
cyst. Embryonic stem cells are derived from the cells of the inner cell mass and can
be cultured indefinitely while retaining the ability to differentiate into cell types from
the three embryonic germ layers endoderm, mesoderm, and ectoderm.
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fluence gene expression by acting as cis-regulatory elements and can also recruit
transcription factors [33][34]. Taken together, these data are beginning to shed light
on the importance of the noncoding genome and repetitive regions in particular.
In addition to the increased study of functional elements in the genome, advances
in sequencing technology have identified new ways to study DNA organization. DNA
does not exist as a naked double helix, rather it interacts with proteins. The mixture of
proteins and DNA in the nucleus is known as chromatin. Chromatin can be visualized
microscopically as tightly compacted chromosomes in dividing cells [35] to diffuse
distributed strands with dense heterochromatic regions during interphase [36]. The
fundamental protein components comprising chromatin are histones. Core histones,
H2A, H2B, H3, and H4, are among the most highly conserved eukaryotic proteins
known, suggesting that chromatin evolved from a common ancestor of eukaryotes
[37].
The nucleosome, the principal subunit of chromatin, consists of the DNA polymer
wrapping twice, apporiximately 147 base pairs (bp), around the combination of two
H2A, H2B, H3, and H4 proteins[38][39]. Individual nucleosome core particles are
connected by short segments of “linker” DNA ranging from 10-80 bp. Histone H1
binds to the linker region, stabilizing the connecting nucleosome core particles. These
fibers can then be folded into a 30-nm structure which results in approximately 50-
fold compaction[37]. The polynucleosome structures can be further compacted into
higher order structures such as the mitotic chromosome. This compaction, initially
started by the nucleosome core particle, allows for nearly two meters of DNA to fit
within a six-micron nucleus.
Chromatin, not naked DNA, is the predominant unit within the nucleus. Therefore,
nucleosomes serve a role beyond compaction by regulating access to DNA templated
processes such as gene expression. In most cases, the eviction, destabilization, or
repositioning of nucleosomes is necessary to facilitate access to the underlying DNA.
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Chromatin organization and rearrangement has been an intensely studied process,
resulting in the elucidation of three general mechanisms. First, chromatin remodeling
can occur by specific protein complexes whose tasks are to slide and evict nucleo-
somes [40]. Second, various post-translational modifications, including acetylation,
methylation, ubiquination, phosphorylation, and others, can occur at the histone tails
creating biochemical signposts that can act as binding sites for the recruitment of
specific proteins [41]. Lastly, alternative histones, such as H2A.Z or H3.3, may re-
place one or more of the core histones creating a destabilized nucleosome leading to
a more permissive environment for regulatory factor binding [42][43].
1.3 Epigenetics and differentiation of ESCs
Histone modifications and variants can persist across generations leading to them
being termed “epigenetic”, yet this classification remains controversial [44]. Epige-
netic modifications are responsible for the incredible amount of cell-type diversity.
Each nucleated cell within the human body contains of the exact same genetic mate-
rial, yet the chromatin landscape is organized differently in each cell type. This altered
organization regulates access of the underlying DNA to transcription factors. The
chromatin environment is coordinated by host of factors ranging from DNA methyla-
tion to covalent histone modifications. Many of the proteins responsible for regulating
chromatin are essential to development, as knockouts in mice have lead to embryonic
lethality [45][46][47].
Acetylation, a histone post-translational modification that decreases the affinity
of the protein-DNA interaction, is associated with active regions of chromatin by in-
creasing access for regulatory factors [48]. The steady state of histone acetylation
is coordinated by both the addition and removal of acetylation by histone acetyltrans-
ferases (HAT) and histone deacetylases (HDACS) respectively. In ESCs HATs have
been demonstrated to directly regulate the pluripotency transcription factors, OCT4
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and NANOG, as well as their downstream targets. Knockdown of specific HATs re-
sults in loss of pluripotency, suggesting that HATs, and acetylation, are important for
maintaining the pluripotent chromatin environment of the ESC [49][50][51].
Recent evidence has demonstrated that the chromatin environment of ESCs is
distinct from differentiated cells. Microscopy of both ESC and differentiated cell nu-
clei has revealed that ESCs contain less heterochromatic regions [36][52]. Consis-
tent with more “open” chromatin by microscopy, biochemical analysis of ESCs have
demonstrated higher levels of acetylated histones with concomitant decrease in re-
pressive histone modifications relative to differentiated cells [5][53]. Consequentially,
ESC also demonstrate an increase in basal gene expression relative to differentiated
cells [54].
Chromatin remodeling is necessary for proper differentiation [55]. Evidence sug-
gests that stem cell chromatin appears poised for differentiation into various lineages
as developmentally important gene promoters as well as enhancers, are bivalent in
ESCs. Bivalent regions are marked concomitantly by active and repressive chromatin
associated histone modifications [56] [57][58]. As cells terminally differentiate the ma-
jority of bivalent genes become monovalent or lose the marks altogether, suggesting
an importance in multipotency [59]. In addition, during terminal differentiation, the
chromatin environment undergoes an overall increase in H3K9 dimethyl and H3K9
trimethyl, histone marks associated with repressive chromatin, demonstrating a gen-
eral increase in compaction of the chromatin environment [60][53].
1.4 Stem cells and cancer
Mesenchymal stem cells (MSC) were first identified by Alexander Friedenstein in
the 1960’s. He detailed a population of cells from mouse bone marrow that could
form connective tissue and bones [61]. In 1999, Pittenger et al. demonstrated that
human bone marrow contained a distinct population of cells which had the mulitpotent
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capacity to differentiate into adipocytes, osteoblasts, and chondrocytes [62]. In vitro
these cells are characterized by their ability to adhere to plastic, positive expression
of cell surface markers CD73, CD90, CD105, and negative expression of a range of
hematopoietic specific cell surface markers including CD34, and CD45 [63][64].
Sarcomas, distinct from carcinomas, are a heterogeneous group of tumors thought
to arise from mesenchymal tissues such as bone, fat, muscle, and cartilage [65]. Sar-
comas are broadly classified into two groups with distinct features. The first, which
includes Ewing sarcoma, is characterized by by the presence of specific transloca-
tions while the other group, represented by tumors such as osteosarcoma, is defined
by complex karyotypes indicative of chromosomal instability [66][67].
Many studies have begun to link MSCs with the origins of sarcomas. Comparing
gene expression profiles of various sarcomas to that of MSCs have demonstrated
similarities [68][69]. One study found a correlation in gene expression between stage
of MSC adipocyte differentiation and specific subtypes of liposarcoma [70]. Further
evidence implicating stem cells as the origin for sarcomas comes from the observa-
tion of spontaneous transformation in mouse MSCs [71][72]. Though human MSCs
have not been shown to undergo spontaneous transformation [67], transformation
can occur upon ectopic expression hTERT, with cells acquiring anchorage indepen-
dent growth and the ability to form tumors in mice [73][74]. Due to the tissues for
sarcomas being mesenchymal in origin, and the data linking MSCs with transforma-
tion, it is intriguing to consider MSCs as the origin for many sarcomas.
1.5 Ewing sarcoma
Ewing sarcoma was first described by James Ewing in 1921 as a diffuse endothe-
lioma of the bone that, unlike osteosarcoma, was sensitive to radiation [75]. This
disease, Ewing sarcoma, the second most common bone and soft tissue malignancy
in children and young adults has an incidence of 2.93 cases per million [76]. Though
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rare, Ewing sarcoma is an aggressive disease where 28% of patients present with
metastasis and treatment consists of intensive chemotherapy, radiation, and surgery.
Nearly 50% of patients will ultimately succumb to the disease within 10 years [76].
The identification of a characteristic fusion between the genes EWSR1 and FLI1
(t(11;22)(q24:q12)) in 1992 greatly enhanced our knowledge of the etiology of this
disease and served as foundation for future research projects [77][78]. The translo-
cation results in a novel transcription factor with transformative potential. Since that
discovery, all cases of Ewing sarcoma are defined by the presence of a fusion be-
tween EWSR1 and an ETS family transcription factor where 85% of the cases are
characterized by the specific fusion of EWSR1-FLI1.
Ewing sarcoma had been traditionally classified histologically as a poorly differ-
entiated small round blue cell tumor and was once thought to arise from primitive
neuroectodermal cells [79]. Early neural markers as well as neural structural features
have been observed in a subset of primary tumors [80][81]. In addition, expression of
EWSR1-FLI1 in neuroblastoma cell lines gives cells characteristics of Ewing sarcoma
[82].
Despite this evidence suggesting a neuronal precursor, the origin of Ewing sar-
coma remains highly controversial. Neural features of Ewing sarcoma are found only
in a minority of patients. In addition, EWSR1-FLI1 expression induces neuroectoder-
mal differentiation and activates genes associated with neural differentiation suggest-
ing that the neural features may be a consequence of EWSR1-FLI1 expression rather
than features of the cell of origin [83][84].
An alternative hypothesis suggest that Ewing sarcoma develops from a MSC.
Knockdown of EWSR1-FLI1 in Ewing sarcoma cells leads to many similarities with
MSCs such as gene expression, capacity for multi-lineage differentiation, and ex-
pression of MSC cell surface markers [68]. Additionally, a subpopulation of cells, iso-
lated from primary tumors and characterized by CD133 expression, has been demon-
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strated to differentiate into adipocytes, osteoblasts, and chondrocytes, a hallmark of
MSCs [85].
EWSR1-FLI1 is aberrant transcription factor that is necessary but not sufficient
for Ewing sarcoma tumor development. Studies exogenously expressing EWSR1-
FLI1 in normal murine and human fibroblasts fail to transform, but instead undergo
growth arrest [86][87]. However, both domains of the fusion protein are critical as
disruption of either the EWSR1 or FLI1 impairs the functional activity of this protein
[78][88]. EWSR1-FLI1 is retargeted to regions distinct from the parental protein FLI1
in a cell-type specific manner [89][90]. Most of EWSR1-FLI1 binding sites act as a
transcriptional activator of nearby genes that are important for Ewing sarcoma includ-
ing IGF1 [91][89][92][93][94]. In addition, binding of EWSR1-FLI1 is able to change
the local chromatin environment by increasing FAIRE signal at these target regions
[90]. EWSR1-FLI1 binding sites in the cancer are also accompanied by increases in
histone post-translational modifications associated with enhancer activity [90][95].
1.6 Chromatin accessibility by FAIRE-seq
Traditionally, chromatin accessibility assays have performed by enzymatic cleav-
age of DNase in a variety of organisms, including plants [96][7][97][98][99]. An alter-
native to DNase is formaldehyde assisted isolation of regulatory elements (FAIRE).
Instead of relying on DNase-I specific enzymatic cleavage of “open” chromatin, FAIRE
utilizes an organic extraction that enriches for a variety regulatory regions in chro-
matin that are “active” or available and consequently thought to be nucleosome de-
pleted [100][101]. Though both techniques assay chromatin accessibility, FAIRE is
more efficient at identifying distal regulatory elements [102]. Applying this technique,
we can compare the chromatin environment of stem, differentiated, and cancer cells
to gain insight into developmental and disease processes.
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1.7 Thesis contributions
The experiments described here show how sequencing serendipitously identified
a loss of tumor suppressor and how this loss effected response to therapies (Chapter
2). In addition, the experiments described here will demonstrate that stem cells have
a unique chromatin environment that can be exploited by the oncoprotein EWSR1-
FLI1 (Chapter 3). The results from these studies have contributed to our understand-
ing of both cancer and stem cell biology as well as providing a potential mechanism
for why specific therapies fail a subset of patients (Chapter 4).
This work has been both collaborative and highly interdisciplinary spanning bio-
chemistry, genomics, molecular and cellular biology. In Chapter 2, the Flourescent
in-situ hybridization (FISH), colony formation, and chloroquine treaments were con-
ducted by Mukund Patel and Andrew McFadden. I performed the OSI-906 inhibitor
experiments, and analyzed the immunohistochemistry (IHC) from the tumor microar-
ray as well as the autophagy results.
In Chapter 3, I performed and anlayzed the FAIRE-seq, RNA-seq, Salt-fractionation,
Immunoblot, and flow cytometry for the cell lines tested. Raluca Dumitru cultured and
differentiated the hESC. Jeremy Simon, Austin Hepperla, and Fang Fang, assisted
with bioinformatics analyses by creating scripts and pipelines related to the project.
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CHAPTER 2
WIDESPREAD CHROMATIN ACCESSIBILITY AT REPETITIVE ELEMENTS
LINKS STEM CELLS WITH HUMAN CANCER
2.1 Introdution
Early mammalian development necessitates precisely regulated transcriptomic
and chromatin changes as cells commit to their terminal fates [156][157][158]. A
comprehensive understanding of chromatin remodeling during differentiation may re-
veal biological pathways that regulate this process and could suggest therapeutic
opportunities relevant to cancer-directed and regenerative medicine. Human embry-
onic stem cells (hESCs), derived from the inner cell mass of human blastocysts, can
propagate in vitro and are able to undergo multi-lineage differentiation [17].
Previous studies have explored chromatin dynamics during stem cell differentia-
tion by comparing hESCs to differentiated cells. hESCs are characterized by ele-
vated levels of activation-associated histone post-translational modifications, histone
bivalency at developmentally regulated genes, and increased expression of variant
histones [56][159][5][53]. Though insightful, histone modification changes represent
one of multiple strategies that ultimately regulate the chromatin landscape.
In an effort to comprehensively explore the changes in chromatin organization
that accompany differentiation, we utilized FAIRE-seq, an unbiased biochemical as-
say that enriches for localized regions of nucleosome-depleted (“open”) chromatin
[101][100]. Regions identified by FAIRE-seq contain a broad range of regulatory
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classes. We applied this technique to compare the chromatin landscape of hESC,
primary and in vitro differentiated mesenchymal stem cells and mature cell lines. We
identified increased chromatin accessibility at specific classes of repetitive elements
in stem cells. These regions harbored distinct histone modifications and underwent
chromatin remodeling during differentiation. Chromatin accessibility at repetitive ele-
ments in stem cells offered a permissive environment that could be exploited by an
oncogenic transcription factor.
2.2 Results
2.2.1 FAIRE selected chromatin from human embryonic stem cells is dominated by
repetitive elements
To explore chromatin organization in human embryonic stem cells, we performed
FAIRE-seq on undifferentiated H1-ESC (WA01), H7-ESC (WA07), and H9-ESC (WA09)
cells. Using bowtie [160], we aligned sequencing reads to the human genome, as
previously described [161]. Consistent with published results in a wide range of cells,
FAIRE signal was enriched at transcriptional start sites (TSS) and CTCF binding sites
in all hESC (Figure 2.1 A)[161]. We also observed signal enrichment at OCT4 and
NANOG binding sites, factors critical for the maintenance of pluripotency (Figure 2.1
A) [162][163].
We then identified genomic regions that were unique to stem cells. We compared
z-score-transformed FAIRE signal in 500 bp windows to publicly available data from
three differentiated cell types (HUVEC, K562, and NHEK) [164]. Of the regions that
passed a minimum signal filter, we identified those that demonstrated a significant
difference between hESC and the three differentiated cell types (p ≤ 0.01, t-test). Hi-
erarchical clustering resolved these 12,026 regions into two major groups (Figure 2.2
A). Cluster 1 (C1) consisted of regions with increased FAIRE signal in hESCs, and
cluster 2 (C2) contained regions with higher signal in the differentiated cell lines (Fig-
12
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Figure 2.1: ESC FAIRE-seq displays expected signal characteristics as well as en-
richment of repetitive elements. (A) FAIRE-seq signal demonstrates enrichment at
known regulatory elements. Average FAIRE-seq signal in H1, H9, H7 at transcrip-
tion start sites (TSS), CTCF, NANOG, and OCT4 binding sites. (B) Repetitive and
Transcription categories are specifically enriched in Cluster 1. Permutation results of
equal number of regions for either C1 and C2 and their association with ChromHMM
classifications. Error bars represent standard deviations of the permuted sets. (C)
Repetitive element enrichment is independent of q-value threshold. Enriched regions
defined by MACS2 were filtered with increasing q-values and intersected with repet-
itive elements. Fraction of regions intersecting a repetitive element (gray bar) and
number of regions exceeding selected q-values (black box) are shown.
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ure 2.2 A and B). The two clusters demonstrated significant differences in location.
C1 regions were primarily distal, with a median distance of 39.5 Kb to the nearest
TSS. Whereas C2 regions were primarily proximal, with a median distance of 11.4
Kb (Figure 2.2 A). We then annotated the genomic intervals with classifications pre-
viously generated by segmentation analyses in H1-ESC, HUVEC, K562, and NHEK
(ChromHMM) [164][165][166]. Briefly, segmentation analyses employs a set of his-
tone modifications to develop a classification scheme for genomic regions linked to
recognized function. C1 was significantly enriched for transcription and heterochro-
matic/repetitive states (p < 0.001, Figure 2.2 A and Figure 2.1 B). In contrast, C2 was
enriched for states such as active and poised promoters, as well as insulators. (p <
0.001, Figure 2.2 A and Figure 2.1 B). Interestingly, despite the striking difference in
FAIRE signal between cell types, regions in these clusters were similarly classified.
Taken together, these data revealed widespread accessible chromatin in stem cells
at genomic regions classified as heterochromatic.
To further characterize FAIRE selected chromatin, we identified 610,887 regions
with significant signal enrichment (peaks) in H1-ESC, 243,467 in H7-ESC, and 384,162
in H9-ESC (MACS2) [167]. Using a false discovery rate threshold, we selected the
top 150,000 peaks for further analysis. The filtered regions were then intersected
with repetitive elements defined by RepeatMasker [168], requiring that the site of
greatest FAIRE signal was within one bp of a repetitive element. Strikingly, we found
that over 82.9%, 94.6% and 94.0% of peak summits identified in H1-ESC, H9-ESC,
and H7-ESC, respectively, intersected a repetitive element. The degree of overlap
for each hESC was significantly greater than HUVEC, NHEK, K562, and a randomly
permuted peak set (Figure 2.2 C). Varying the stringency parameters used to select
peaks had no effect on fractional overlap (Figure 2.1 C).
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2.2.2 Simple repeats and SINEs are enriched in FAIRE selected chromatin
We then assessed whether the enrichment of repetitive elements was restricted to
specific classes. Simple repeats and short interspersed nucleotide elements (SINEs)
were selectively enriched among FAIRE peaks in hESC, relative to their genomic
prevalence. This pattern was not observed in the three differentiated cell types (Fig-
ure 2.2 D).
In further support of repetitive element enrichment, we also found that a large
fraction of sequencing reads from each hESC line was discarded during alignment
due to redundant genomic mapping (Table 2.1). 83% of unaligned sequences from
H1-ESC were repetitive in nature, enriched for SINEs, simple repeats, and LINEs
(Table 2.2). In contrast, similar analysis of HUVEC FAIRE identified only 51% of
discarded reads as repetitive sequences, a fraction consistent with the abundance of
these elements genome-wide.
We then assayed FAIRE signal differences in each repeat class. After normalizing
for repeat length and sequencing depth, signal in hESC at simple repeats and SINEs
greatly exceeded that of differentiated control cells (Figure 2.2 E). In contrast, signal
differences at LINEs were minimal and DNA transposons demonstrated an inverse
relationship. Taken together, read, signal and peak-based detection approaches con-
sistently identify the selective enrichment of simple repeats and SINEs by FAIRE in
hESCs.
2.2.3 FAIRE-enriched repeats are shared across hESCs and exhibit distinguishing
features
Simple repeats and SINEs consist of thousands to millions of individual regions.
Only a small fraction was identified by FAIRE (<5% of each class, Table 2.3). We
then asked if these regions were consistently identified across hESC lines. Among
simple repeats and SINEs with signal in the top quartile a large fraction were shared
15
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Figure 2.2: FAIRE-seq enriched regions specific to hESC are dominated by simple
repeats and SINEs. (A) Heatmap of those regions with significantly different FAIRE
enrichment between hESC and control HUVEC, K562, NHEK (500 bp windows, p ≤
0.01, t-test, rowmax – rowmin > 3). Regions were assigned classes based on distance
to nearest TSS (<10 Kb red, 10-20 Kb white, >20 Kb blue and by segmentation
analysis [164]. (B) Genome browser images of representative regions selected from
Cluster 1 (top panel), Cluster 2 (middle panel), and a Control region (bottom panel).
(C) Fraction of top 150,000 peak summits that overlapped a repetitive element in
hESCs (green) and controls (blue). Fractional overlap with an H1-ESC permuted
peak set (red line) and standard deviation (dashed lines) are shown. (D) Heatmap de-
picting the enrichment of specific classes of repetitive elements in MACS2-identified
FAIRE-enriched regions, relative to genomic coverage. (E) Normalized FAIRE signal
at Simple Repeats, SINEs, DNA Transposon, and LINE in hESC (green) and control
cell lines (blue) plotted by quartile. 16
Sample Total
Raw
Reads
(106)
Total
Reads
Pass-
ing
Tag-
dust
(106)
Median
Read
Qual-
ity
Score
Reads
lost to
multiple
align-
ment
(106)
% lost to
multiple
align-
ments
Total
Aligned
Reads
(106)
Percent
of Raw
Reads
Suc-
cessfully
Aligned
Percent of
TagDust fil-
tered Reads
Successfully
Aligned
H1-hESC
FAIRE
Rep 1
86.19 83.83 36.4 23.55 27.32 49.20 57.1 58.7
H1-hESC
FAIRE
Rep 2
86.44 83.17 36.3 22.11 25.58 50.50 58.4 60.7
H9-hESC
FAIRE
80.35 79.96 37.8 23.05 28.69 44.10 54.9 55.2
H7-hESC
FAIRE
54.27 54.22 35.8 17.93 33.04 27.59 50.8 50.9
HUVEC
FAIRE
Rep1
58.84 58.69 29.9 15.65 26.67 39.53 67.2 67.4
HUVEC
FAIRE
Rep2
48.99 48.77 29.5 12.66 25.96 33.62 68.6 68.9
NHEK
FAIRE
REP1
66.30 65.97 29.42 11.71 17.75 51.83 78.2 78.6
NHEK
FAIRE
Rep2
129.99 127.39 29.66 22.74 17.85 98.98 76.2 77.7
K562
FAIRE
Rep1
64.28 64.23 27.19 13.50 21.02 48.87 76.0 76.1
K562
FAIRE
Rep 2
64.17 64.12 28.51 15.28 23.83 46.84 73.0 73.1
Table 2.1: Read Count and Mapping Statistics
by at least one other hESC line (simple repeat: 48%, 86949 of 179379; SINEs: 59%,
423,819 / 723415; p < 0.001 by permutation) (Figures 2.3 A and 2.4 A Figure 2.3
D and 2.4 C). Consistent with a central role of the repetitive segment in mediating
chromatin state, we found that for both simple repeats and SINEs FAIRE signal was
centered at the repetitive element, rather than extending from flanking regions, and
was concordant between the stem cells (Figures 2.3 B, E and 2.4 B and D).
To explore other factors that may influence chromatin status, we asked whether
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Sample Total
Length
of Un-
alinged
reads
(106bp)
% of
se-
quence
SINE
% of
se-
quence
LINE
% of se-
quence
LTR
% of se-
quence
DNA
% of
se-
quence
sim-
ple
repeat
% of se-
quence
Other
Total
repet-
itive
bases
(106bp)
%
Repet-
itive
H1-
hESC
1873.89 40.50 21.46 1.82 0.09 9.26 9.98 1557.63 83.1
HUVEC 687.62 22.78 17.05 6.19 1.18 2.29 3.95 367.45 53.4
Table 2.2: Percentage of Masked Bases from Unaligned Reads.
length and G/C content distinguish those repeats that are FAIRE-enriched. For sim-
ple repeats, the lengths of FAIRE-enriched and FAIRE-negative sites varied little.
However, enriched sites demonstrated a significant skew towards higher G/C content
(Figure 2.3 C). The opposite pattern was observed for SINEs. FAIRE-enriched SINEs
were significantly longer than others whereas G/C content differed only slightly (Fig-
ure 2.3 F). Overall, FAIRE identifies repetitive elements that are common to multiple
hESCs and demonstrate shared chromatin patterns and distinct class-specific DNA
features.
2.2.4 FAIRE and DNase differ at repetitive regions
Given the abundance of FAIRE-enriched repeats, we were surprised that chro-
matin accessibility at these sites had not been previously observed. As a comple-
Repeat
Class
Total
Elements
in Repeat
Masker
# Found
in Peaks
% Found
in Open
Chro-
matin
Simple
Repeat
417913 16975 4.062
SINE 1793723 26304 1.466
LINE 1498690 28151 1.878
Satellite 9566 529 5.530
DNA
Transpo-
son
461751 579 0.125
LTR 717656 544 0.076
Table 2.3: Percentage of Repeats Found in H1-ESC FAIRE (+) Chromatin
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Figure 2.3: hESC share FAIRE signal enrichment at Simple Repeats and SINEs. A)
The union set of simple repeats with FAIRE signal in the top quartile (Q4) for hESC
are shown. (p < 0.001, permutation based on all simple repeats). (B) Heatmap
demonstrating FAIRE signal at simple repeats grouped by categories (colors defined
in A) with Distance represents bp from the center of the simple repeat. (C) Lengths
(left) and G/C content (right) of simple repeats that are FAIRE-enriched (+) in all
hESC (see panel A, n = 27,948) and an equal number of randomly selected simple
repeats from quartile 1 (FAIRE −). (D) The union set of SINEs with FAIRE signal
in the top quartile (Q4) for hESC are shown. (p < 0.001, permutation based on all
SINEs). (E) Heatmap demonstrating FAIRE signal at SINEs grouped by categories
(colors defined in D). Distance represents bp from the start of the SINEs. (F) Lengths
(left) and G/C content (right) of SINEs that are FAIRE-enriched (+) in all hESC (see
panel D, n = 180,105) and an equal number of randomly selected simple repeats
from quartile 1 (FAIRE −).
mentary approach, we analyzed DNase hypersensitivity data (DNase). In contrast to
FAIRE, DNase depends on enzymatic digestion to interrogate chromatin accessibility
[7][96]. Leveraging publicly available data, we compared FAIRE and DNase signal at
simple repeats and SINEs at FAIRE peaks (from Figure 2.2 C). Surprisingly, these
regions lacked DNase signal (Figure 2.5 A). Conversely, the few repeats that demon-
strated DNase signal lacked FAIRE enrichment (1099 and 2033 simple repeats and
SINEs, respectively). As a control, we examined FAIRE and DNase at transcription
start sites (TSS) and CTCF sites. FAIRE and DNase positively correlated at these
regions, consistent with published results and confirming the validity of the assays
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(Figures 2.5 B and Figure 2.6 A and B).
Because of the discrepancy between FAIRE and DNase at repetitive regions, we
then explored nucleosome positioning using published MNase-seq data [169]. By
cleaving DNA in the linker region between two nucleosomes, MNase-seq offers in-
sight into the location of nucleosomes. DNase-positive regions, including those in
repeats, TSS, and CTCF binding sites, demonstrated decreased MNase signal, con-
sistent with nucleosome depletion (Figure 2.5 A). However, FAIRE-enriched SINEs
and shorter simple repeats exhibited the presence of one to two well-positioned nu-
cleosomes. Of note, phased nucleosomes flanked both classes of repeats, similar to
patterns observed at other regulatory elements (Figure 2.5 B) [170][171].
To further characterize the relationship between FAIRE and nucleosome position-
ing at repetitive regions, we examined MNase signal at all simple repeats grouped
by the magnitude of FAIRE enrichment. Mnase signal was greatest at regions with
highest FAIRE enrichment. Further, regions with the greatest FAIRE signal demon-
strated the presence of a single centered nucleosome (Figure 2.5 C). For all regions,
we observed symmetrical nucleosome phasing extending beyond the repetitive re-
gion. Overall, these data indicate that, in contrast to the recognized association of
Figure 2.4: Permutation Results, signal correlation, and signal characteristics. (A)
To establish a baseline for comparison, permuted sets of simple repeats were inter-
sected for 1000 iterations and overall relationships are depicted in the Venn diagram
(top). Mean numbers of sites for each region +/− standard deviation is shown. Frac-
tion of regions that were in common for at least two ESC lines (H1, H9, H7), or a per-
muted control set (bottom). (B) hESC FAIRE signal at simple repeats demonstrate a
positive correlation. Signal was plotted pair-wise for each cell line and a Spearman
correlation measured. (C) To establish a baseline for comparison, permuted sets of
SINE were intersected for 1000 iterations and overall relationships are depicted in the
Venn diagram (top). Mean numbers of sites for each region +/− standard deviation
is shown. Fraction of regions that were in common for at least two ESC lines (H1,
H9, H7), or a permuted control set (bottom). (D) Average FAIRE signal at H1, H9,
H7, and HUVEC at union set of top quartile FAIRE regions. H1 demonstrate bimodal
signal at SINE in top quartile FAIRE regions.
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FAIRE with nucleosome depletion, in the context of these regions, FAIRE identifies a
chromatin organizational feature characterized by the presence of nucleosomes.
2.2.5 Distinct histone post-translational modifications demarcate repetitive elements
We then asked whether specific histone modifications distinguish the nucleosomes
at accessible repetitive elements. We compared H1-ESC ChIP-seq data for a range
of histone modifications at FAIRE-enriched and FAIRE-negative sites [172]. We found
that FAIRE-enriched simple repeats were marked by specific acetylated histones (Fig-
ure 2.7 A). Associated modifications differed from those at FAIRE-enriched SINEs as
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Figure 2.5: Nucleosome-bound repetitive regions are identified by FAIRE. (A)
Heatmap representations of H1-ESC FAIRE-seq, DNase, and MNase-seq signal
[169] at FAIRE-enriched (FAIRE +) or DNase-enriched (DNase +) simple repeats
and SINEs rank ordered by length. For reference, repeat positions (defined by Re-
peatMasker) are also plotted. (B) Heatmaps of H1-ESC FAIRE-seq, DNase, and
MNase-seq signal at transcription start sites (TSS) and CTCF sites. (C) H1-ESC
MNase-seq signal at simple repeats grouped by quartiles of FAIRE signal. An equal
number of random genomic windows are plotted for comparison (control, green).
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well as TSS and CTCF sites (Figure 2.7 A). H3K56ac and H2AK5ac were most as-
sociated with simple repeats. Signals for these modifications were centered over
the repeat and demonstrated a magnitude similar or greater than that found at TSS
and CTCF sites. (Figures 2.7 B and 2.8). H4K8ac and H2A.Z were most associ-
ated with SINEs and show subtle but center-weighted enrichment (Figures 2.7 C and
2.9). Overall, these data indicate that FAIRE-enriched simple repeats and SINEs are
characterized by distinctly marked nucleosomes.
As an alternative approach to explore chromatin accessibility, we performed salt
fractionation of MNase treated nuclei. Salt fractionation separates chromatin based
on physical properties [173]. Low salt-soluble regions are enriched for active and
highly accessible chromatin, whereas high salt solubilizes the bulk chromatin fraction
[174]. Salt fractionation both allows for direct comparisons of nucleosome composi-
tion in active chromatin as well as the positioning of individual nucleosomes by high-
throughput sequencing. Nucleosomes were extracted from nuclei of H1-ESC and
a differentiated control (Human Kidney Cells, HKC) using increasing concentrations
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Figure 2.6: FAIRE and DHS correlate at TSS and CTCF sites. (A) Log2 transformed
FAIRE and DHS signal at TSS (+/- 300 bp) or CTCF sites (+/- 200 bp) were plotted.
Spearman correlation is shown.
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of salt. The low salt fraction from both cell types consisted predominantly of mono-
nucleosomes whereas the high salt fraction consisted of mostly di-nucleosomes (Fig-
ure 2.10), consistent with published results [175]. Histone post-translational modifica-
tions associated with each fraction were assayed by immunoblot. As predicted by our
informatic analyses, H2AK5ac was significantly enriched in low salt fractions of nu-
cleosomes from stem cells when compared to the differentiated control cells (p-value
< 0.05, Figure 2.7 D). This enrichment did not extend to the high salt or insoluble
chromatin.
To identify nucleosome positioning at repetitive elements in highly accessible chro-
matin, we sequenced the DNA in both low and high salt soluble fractions and plotted
the signal at simple repeats (Figure 2.7 E). We again identified nucleosome phasing
flanking the repeats in both H1-ESC and the differentiated control cells. However,
compared with the differentiated cell control, H1-ESC demonstrated an increase in
MNase signal at the center of the repeat exclusively in low salt extracted chromatin,
indicative of a highly extractable nucleosome. Taken together with the immunoblot
and ChIP-seq analysis, these data indicate that specific acetylation is associated
with nucleosomal destabilization but not displacement at repetitive elements.
2.2.6 Repetitive regions undergo chromatin remodeling during differentiation
The difference in FAIRE enrichment at repetitive elements in stem and differen-
tiated cells led us to test whether these elements undergo remodeling during dif-
ferentiation. H1-ESC embryonic stem cells were differentiated in culture towards a
mesenchymal lineage (H1-MSC). The mesenchymal lineage consists of mesenchy-
mal stem cells (MSC) that can terminally differentiate into diverse range of cells [62].
Differentiation of hESC to MSC was validated using several approaches. Mor-
phologically, H1-MSCs acquire a fibroblastic appearance in contrast to the spherical
colonies of H1-ESC (Figure 2.11 A). The multipotency of H1-MSC was demonstrated
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Figure 2.7: Distinct histone modifications characterize FAIRE-enriched repeats. (A)
Heatmap of ranked histone posttranslational modifications. Differential ChIP signal
comparing FAIRE-enriched (+) with FAIRE-negative repeats (simple repeat +/− 250
bp from center or SINEs start to +300 bp) was rank ordered. For comparison, signal
at TSS or CTCF (+/−500 bp) was rank ordered. Histone modification by acetylation
is highlighted (green). (B) Mean H1-ESC ChIP signal of selected histone posttransla-
tional modifications at H1-ESC FAIRE-enriched (red line) and FAIRE-negative (black
line) simple repeats, and control regions (TSS green line, CTCF blue line). (C) Mean
H1-ESC ChIP signal of H4K8ac and H2A.Z at H1-ESC FAIRE-enriched (red line) and
FAIRE-negative (black line) SINEs, and control regions (TSS green line, CTCF blue
line). (D) Salt fractionated nuclear extracts from H1-ESC and HKC (differentiated cell)
were immunoblotted with anti-H2AK5ac (green) and anti-pan-H3 (red). Fluorescence
intensity was quantified and normalized to H3. (E) Mean H1-ESC and HKC (differen-
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Figure 2.8: Histone modifications at simple repeat. (A) ChIP signal for available
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by further differentiation into osteoblast and adipocyte lineages, as demonstrated by
Alizarin red and Oil Red O staining (Figure 2.11 A). Finally, flow cytometry of H1-MSC
identified a robust increase in CD90, CD73, CD105, and CD44, cell surface markers
also detected on primary bone marrow-derived MSC (BM-MSC) (Figure 2.11 B). H1-
ESC were negative for CD73 and CD105.
FAIRE-seq was then performed on primary BM-MSC and H1-MSC. We identified
25,000 SINEs and 4,700 simple repeats with significantly different FAIRE signal be-
26
A
Histone modifications across SINE
0 500 1000 1500 2000
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
ESC H2A.Z SINE
Index
ES
C_
H2
A.
Z_
SI
NE
_c
on
tro
l_1
[, 
1]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
3.
0
3.
5
4.
0
4.
5
5.
0
ESC H2AK5ac SINE
Index
ES
C_
H2
AK
5a
c_
SI
NE
_c
on
tro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
4
6
8
10
ESC H2BK5ac SINE
Index
ES
C_
H2
BK
5a
c_
SI
NE
_c
on
tro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
3
4
5
6
ESC H2BK12ac SINE
Index
ES
C_
H2
BK
12
ac
_S
IN
E_
co
nt
ro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
ESC H2BK15ac SINE
Index
ES
C_
H2
BK
15
ac
_S
IN
E_
co
nt
ro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
4.
0
4.
5
5.
0
5.
5
6.
0
ESC H2BK20ac SINE
Index
ES
C_
H2
BK
20
ac
_S
IN
E_
co
nt
ro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
ESC H2BK120ac SINE
Index
ES
C_
H2
BK
12
0a
c_
SI
NE
_c
on
tro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
5
6
7
8
9
10
11
ESC H3K4me1 SINE
Index
ES
C_
H3
K4
m
e1
_S
IN
E_
co
nt
ro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
5
10
15
20
25
30
ESC H3K4me2 SINE
Index
ES
C_
H3
K4
m
e2
_S
IN
E_
co
nt
ro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
0
50
10
0
15
0
ESC H3K4me3 SINE
Index
ES
C_
H3
K4
m
e3
_S
IN
E_
co
nt
ro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
10
20
30
40
ESC H3K9ac SINE
Index
ES
C_
H3
K9
ac
_S
IN
E_
co
nt
ro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
5
6
7
8
9
10
ESC H3K9me3 SINE
Index
ES
C_
H3
K9
m
e3
_S
IN
E_
co
nt
ro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
3
4
5
6
7
8
ESC H3K14ac SINE
Index
ES
C_
H3
K1
4a
c_
SI
NE
_c
on
tro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
2
3
4
5
6
7
8
ESC H3K18ac SINE
Index
ES
C_
H3
K1
8a
c_
SI
NE
_c
on
tro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
ESC H3K23ac SINE
Index
ES
C_
H3
K2
3a
c_
SI
NE
_c
on
tro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
3
4
5
6
7
8
ESC H3K23me2 SINE
Index
ES
C_
H3
K2
3m
e2
_S
IN
E_
co
nt
ro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
2
4
6
8
10
12
14
ESC H3K27ac SINE
Index
ES
C_
H3
K2
7a
c_
SI
NE
_c
on
tro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
5
6
7
8
9
ESC H3K36me3 SINE
Index
ES
C_
H3
K3
6m
e3
_S
IN
E_
co
nt
ro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
3
4
5
6
7
ESC H3K56ac SINE
Index
ES
C_
H3
K5
6a
c_
SI
NE
_c
on
tro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
ESC H3K79me1 SINE
Index
ES
C_
H3
K7
9m
e1
_S
IN
E_
co
nt
ro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
4
5
6
7
ESC H3K79me2 SINE
Index
ES
C_
H3
K7
9m
e2
_S
IN
E_
co
nt
ro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
4
6
8
10
12
ESC H4K5ac SINE
Index
ES
C_
H4
K5
ac
_S
IN
E_
co
nt
ro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
1
2
3
4
5
6
7
ESC H4K8ac SINE
Index
ES
C_
H4
K8
ac
_S
IN
E_
co
nt
ro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
2.
0
2.
5
3.
0
3.
5
ESC H4K20me1 SINE
Index
ES
C_
H4
K2
0m
e1
_S
IN
E_
co
nt
ro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
3
4
5
6
7
8
ESC H4K91ac SINE
Index
ES
C_
H4
K9
1a
c_
SI
NE
_c
on
tro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 500 1000 1500 2000
2
4
6
8
10
12
14
ESC H3K27ac SINE
Index
ES
C_
H3
K2
7a
c_
SI
NE
_c
on
tro
l_1
[1
:2
00
0,
 1
]
FAIRE Positive
FAIRE Negative
TSS
CTCF
Ch
IP
 S
ig
na
l
bp from center of repeat
FAIRE Positive
FAIRE Negative
TSS
CTCF
0 +1000-1000 0 +1000-1000 0 +1000-1000 0 +1000-1000 0 +1000-1000 0 +1000-1000
0 +1000-1000 0 +1000-1000 0 +1000-1000 0 +1000-1000 0 +1000-1000 0 +1000-1000
0 +1000-1000 0 +1000-1000 0 +1000-1000 0 +1000-1000 0 +1000-1000 0 +1000-1000
0 +1000-10000 +1000-10000 +1000-10000 +1000-10000 +1000-10000 +1000-1000
0 +1000-1000 0 +1000-1000
Figure 2.9: Histone modifications at SINE. (A) ChIP signal for available histone mod-
ifications [172] at FAIRE-positive (red), FAIRE-negative (black) simple repeats, TSS
(green), and CTCF binding sites (blue).
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tween hESC and BM-MSC. Unsupervised hierarchical clustering of these regions,
together with signal from H1-MSC as well as HUVEC, NHEK, and K562, revealed
two main clusters (Figure 2.12 A and E). For SINEs, stem cells clustered together
closely whereas differentiated cells segregated into a separate cluster. Notably, the
differentiated H1-MSC exhibited greater similarity to primary BM-MSC than to un-
differentiated H1-ESC. Overall, virtually all sites that exhibit signal variation demon-
strated a progressive decrease in FAIRE enrichment accompanying differentiation.
SINEs with differential FAIRE signal were then associated with genes [176]. Of those
genes that were also differentially expressed, 95% demonstrate greater expression
(> 2-fold) in hESC relative to BM-MSC, compared with 89% for genes associated with
invariable SINEs (Figure 2.12 B) The overall skew to greater message abundance in
hESC is consistent with higher global transcription levels in these cells [54]. Genes
with elevated expression in hESC (Category 1) were linked to terms such as cell cy-
cle whereas those with elevated expression in MSC (Category 2) were linked with
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terms implicating mesenchymal development such as blood vessel development and
response to wounding (Figures 2.12 C and D).
Clustering cell lineages based on FAIRE signal at simple repeats demonstrated
a distinct pattern from that observed based on signal at SINEs. hESC clustered to-
gether, clearly separated from the differentiated cells. MSC, including bone marrow
and H1-derived, clustered closely together but grouped with the differentiated cells.
FAIRE signal at simple repeats revealed two patterns. One pattern was similar to that
seen for the SINEs with progressively decreasing signal associated with differentia-
tion. The other pattern revealed FAIRE signal greater in MSC lineages compared with
either hESC or the differentiated cells (Figure 2.12 E). We again associated these re-
gions with differentially regulated genes. Regions with higher FAIRE signal in hESC
or MSC were associated with genes more highly expressed in hESC or MSC, respec-
tively (compared with invariable region-associated genes) (Figure 2.12 F). hESC-
associated genes were enriched for gene ontologies related to development, such
as tube development and stem cell development, whereas MSC-associated genes
were enriched for pathways linked to mesenchymal development, such as blood ves-
sel development, skeletal system development, and response to wounding (Figures
2.12 G, H and Figure 2.9 C).
Taken together, these results suggest that repetitive elements undergo chromatin
remodeling during differentiation. Repetitive regions with variable accessibility are as-
sociated with changes in lineage-specific gene expression and developmental path-
ways. However, the pattern of remodeling differs between the two classes of repeti-
tive elements. SINEs primarily become inaccessible during differentiation, whereas a
subset of simple repeats become accessible during lineage specification.
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Figure 2.11: Differentiation of H1-ESC to H1-MSC. (A) H1-MSC can differentiate
into osteoblasts and adipocytes. Photomicrographs of H1 ESC prior to differentiation
(phase contrast), intermediately differentiated H1-MSC (phase contrast) and lineage-
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2.2.7 Oncogenic transcription coopts stem cell chromatin
Many sarcomas are thought to originate from stem cells of mesenchymal origin
[67]. To explore this link, we compared the chromatin environment in stem cells with
that in Ewing Sarcoma, the second most common bone malignancy in children and
young adults. Ewing sarcoma is characterized by a chromosomal rearrangement that
creates a novel transcription factor. We and others have previously shown that the
resulting chimeric oncoprotein, EWSR1-FLI1, targets a subset of simple repeats dis-
tinct from the parental protein FLI1 [89]. Further, this targeting is cell-type specific
[89][90]. This observation led us to hypothesize that a permissive chromatin environ-
ment may facilitate this retargeting. We tested for the enrichment of repeat classes
in accessible chromatin in tumor cells and primary BM-MSC. Both tumor cells and
MSC shared high degree of enrichment at simple repeats, relative to other repetitive
element classes (Figure 2.13 A).
Since EWSR1-FLI1 selectively retargets GGAA-containing simple repeats, we ex-
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amined FAIRE signal in BM-MSC and Ewing sarcoma cells at all simple repeats con-
taining this motif, clustering these regions based on their signal in the cancer cells
(Figure 2.13 B). We found a striking similarity in the pattern of chromatin accessibility
between the stem and cancer cells. In BM-MSC, the signal was center-weighted at
about half of the regions (Figures 2.13 B and 2.14 A). For others, regions flanking the
repeat demonstrated the greatest signal.
To explore the connection between chromatin accessibility and EWSR1-FLI1 tar-
geting, we compared FAIRE signal in BM-MSC with EWSR1-FLI1 ChIP signal from
Ewing sarcoma cells. Repeats with the greatest FAIRE signal in BM-MSC demon-
Figure 2.12: Repetitive elements undergo extensive chromatin remodeling during dif-
ferentiation. (A) FAIRE signal from hESC, BM-MSC, H1-MSC, K562, NHEK and HU-
VEC at SINEs characterized by significantly different FAIRE signal between hESCs
and BM-MSCs (t-test p<0.01 and rowmax – rowmin > 3) were z-score transformed
and biclustered. Heatmap scale represents relative z-scores. (B) Fraction of genes
linked to variable FAIRE at repeats that demonstrate differential gene expression (in-
creased in hESC - gray, category 1; increased in MSC - black, category 2). Differen-
tial expression was defined as RPKM > 4 fold change. Control represents an equal
number of randomly selected repeats that did not change significantly during differen-
tiation. (C) Gene ontologies enriched for genes in category 1 from (C). Bars indicate
−log10FDR. (D) Gene ontologies enriched for genes in category 2 from (C). Bars in-
dicate −log10FDR. (E) FAIRE signal from hESC, BM-MSC, H1-MSC, K562, NHEK
and HUVEC at Simple Repeats characterized by significantly different FAIRE signal
between hESCs and BM-MSCs (t-test p<0.01 and rowmax − rowmin > 3) were z-score
transformed and biclustered. Heatmap scale represents relative z-scores. (F) Frac-
tion of genes linked to variable FAIRE at repeats that demonstrate differential gene
expression. Genes associated with increased FAIRE in hESC are further divided,
those associated with genes with increased expression in hESC (gray, category 1)
and those associated with genes with increased expression in MSC (black, category
2). Genes associated with increased FAIRE in MSC are also further divided, those
associated with genes with increased expression in hESC (gray, category 3) and
those associated with genes with increased expression in MSC (black, category 4).
Differential expression was defined as RPKM > 2 fold change. Control represents an
equal number of randomly selected repeats that did not change significantly during
differentiation. (G) Gene ontologies enriched for genes identified in category 1 from
(G). Bars represent −log10FDR. (H) Gene ontologies enriched for genes identified in
category 4 from (G). Bars represent −log10FDR.
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strated the greatest ChIP signal in the tumor cells (Figure 2.14 B). Similarly, EWSR1-
FLI1 targeted those regions for which the maximal FAIRE signal was over the repeat
in BM-MSC (p < 0.001, permutation). We then explored the activity of EWSR1-FLI1
on chromatin. We compared the difference in FAIRE signal between BM-MSC and
the tumor cells with EWSR1-FLI1 ChIP signal. We found a significant correlation be-
tween oncoprotein binding and changes in FAIRE signal (r = 0.74) (Figure 2.13 C).
Taken together, these data lend chromatin-based evidence of an MSC origin for these
tumors and, further, demonstrate that an MSC chromatin pattern predicts EWSR1-
FLI1 oncoprotein targeting.
We then explored chromatin accessibility using enzymatic approaches. Neither
DNase-seq data that we generated from BM-MSC nor published DNase and ATAC
data from these cells identified signal enrichment at regions ultimately targeted by
EWSR1-FLI1 (Figure 2.13 D) [90][95]. The absence of signal is consistent with our
previous observation regarding DNase in hESC (Figure 2.5 A). In contrast, in Ew-
ing Sarcoma cells these regions were detected by DNase and ATAC. Moreover, in
BM-MSC ATAC enrichment was noted at these sites only after EWSR1-FLI1 was
transduced (Figure 2.13 D and [95]). DNase and ATAC signal enrichment was not
observed at similar repeats that did not bind EWSR1-FLI1. These data suggest
that EWSR1-FLI1 targets nucleosome-destabilized regions ultimately evicting nucle-
osomes, a feature which can then be detected using the enzymatic approaches of
DNase and ATAC.
Since EWSR1-FLI1 did not target all GGAA-containing simple repeats, we asked
whether there were other chromatin features that correlated with increased FAIRE
signal in BM-MSC and the ability to bind EWSR1-FLI1. Using ChIP from H1-MSC
[172] we examined histone modifications at those sites that are targeted by EWSR1-
FLI1 in cancer cells. Of histone modifications available for analysis, we noted a subtle
increase in enrichment for H3K14ac, H4K91ac, H2BK12ac, all marks enriched in sim-
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Figure 2.13: Cancer exploits unique chromatin environment of stem cells. (A)
Heatmap depicting the enrichment of specific classes of repetitive elements in
MACS2-identified FAIRE-enriched regions in Ewing Sarcoma (EWS) and BM-MSC
chromatin, relative to genomic coverage. (B) Clustered BM-MSC or EWS FAIRE
signal at all (GGAA)n-containing simple repeats (left). EWSR1-FLI1 ChIP signal in
EWS at (GGAA)n-containing simple repeats (right). (C) Scatterplot of log2 trans-
formed FAIRE change between BM-MSC and EWS and EWSR1-FLI1 ChIP signal
at EWSR1-FLI1 bound (red) or unbound (blue) repeats. Pearson correlation shown.
(D) FAIRE, DNase and ATAC signal at EWSR1-FLI1 binding sites in BM-MSC, Ew-
ing Sarcoma (EWS), and MSCs exogenously expressing EWSR1-FLI1 [95]. Distance
represents Kb from the center of the repeat. FAIRE and DNase data were normalized
to overall read count. ∗ATAC read count was unavailable and consequently not nor-
malized. (E) Fold change of H1-MSC ChIP signal for H3K14ac, H4K91ac, H2BK12ac,
and H3K27ac at repeats bound by EWSR1-FLI1 in Ewing sarcoma cells relative to
an equal number of repeats that were not bound. Distance represents from center of
repeat.
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ple repeats in hESC (Figure 2.13 E). These data suggest that chromatin modifications
specific to stem cells facilitate EWSR1-FLI1 targeting.
2.3 Discussion
By integrating multiple complementary genome-wide approaches we identified a
unique chromatin environment in stem cells marked by accessible chromatin at repet-
itive DNA sequences. Further, we demonstrate that these features offer a permissive
environment for the central oncogenic pathway in Ewing sarcoma.
Though FAIRE-seq revealed the magnitude of this unexpected chromatin signa-
ture in hESC, complementary experimental approaches have yielded results con-
sistent with this observation. An examination of chromatin in murine ESC using
FAIRE similarly demonstrated variation in regions associated with developmental
pathways [177]. Although not addressed in this study, our analysis of these data also
demonstrated enrichment of repetitive elements in mESC compared to MEF (data
not shown). That hESCs had significantly more FAIRE peaks and a generally lower
signal-to-noise ratio than differentiated cells suggests decreased chromatin conden-
sation, consistent with biochemical and microscopic approaches [178][52].
The most characteristic feature associated with the repetitive elements in acces-
sible chromatin was histone acetylation. Variations in histone acetylation have been
linked to stem cell differentiation, and nucleosome acetylation can destabilize DNA-
nucleosome interactions [179][48]. Interestingly, the sites of acetylation enriched at
simple repeats differ from the well-studied H3K27ac and H3K9ac. Segmentation
analysis of stem cells has generally categorized repeats as heterochromatic, however
these modeling approaches have not included atypical marks, such as H2AK5ac. In-
deed, evidence suggests that H2AK5ac enrichment is associated with active regions
of chromatin [180]. Given the paucity of available datasets, features other than his-
tone acetylation may also influence chromatin accessibility. As a functional readout
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Figure 2.14: Regions with increased FAIRE signal in BM-MSC tend to be center-
weighted and associated with EWSR1-FLI1 binding in tumor cells. (A) Repeats were
classified as center-weighted signal or flanking signal using a 200 bp sliding window
with a 100 bp overlap. Distribution of FAIRE signal at the center of the repeat (+/−
200 bp) was plotted. (B) Histogram of BM-MSC FAIRE summed +/− 100bp from the
center of EWSR1-FLI1 at bound (blue) or unbound (white) GGAA-containing simple
repeats and log2 transformed.
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of chromatin states, the inclusion of FAIRE may increase the power of predictive ge-
nomic segmentation.
In support of a functional role for repetitive elements, we observed alterations in
chromatin organization that accompany differentiation. Genes associated with SINEs
that demonstrated differential accessibility exhibited cell cycle pathway enrichment,
consistent with the importance of this pathway in maintaining pluripotency [181].
Similarly, pathways associated with mesenchymal differentiation and function were
enriched among regions with gains in accessibility during differentiation. Interest-
ingly, variation in histone posttranslational modifications between induced pluripotent
stem cells (iPSC) and ESCs has been inconsistently identified [182][60]. Analysis of
iPSC by FAIRE would identify whether chromatin accessibility at repetitive elements
is restored during reprogramming and could contribute to chromatin-based insights
regarding the reprogramming process.
The observation of phased nucleosomes flanking all repetitive elements was also
unexpected. Ordered nucleosomes were observed even in the absence of FAIRE
enrichment and in differentiated cells. Stretches of specific repeated sequences can
bend DNA which may attract nucleosomes, and DNA sequence content can influ-
ence nucleosome position [183][184][185][186]. Our results greatly extend previous
reports suggesting that Alu repeats may serve to pattern nucleosomes [187][188].
A striking result of our study was the extensive similarity between MSC chromatin
and that of Ewing sarcoma. The shared chromatin pattern strongly supports tumor
development from a stem-like population, an observation consistent with studies de-
scribing similarities in gene expression and capacity for in vitro differentiation [85][68].
Further, our results offer a mechanistic explanation for the cell-type specific targeting
of EWSR1-FLI1 in tumor cells. The absence of accessible chromatin at repetitive el-
ements in differentiated cell types may restrict EWSR1-FLI1 targeting offering an ex-
planation of why this oncogene fails to broadly transform cells [189]. Simple repeats,
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when bound by EWSR1-FLI1, gain enhancer activity to regulate the transcription of
multiple genes known to be important for Ewing Sarcoma [89][190][92][93][90][94].
Further, germline variation in repetitive element composition has recently been as-
sociated with disease risk [191][190]. The differences in location and composition of
these repetitive regions relative to critical genes across species may explain the chal-
lenge in generating an animal model that faithfully recapitulates features of Ewing
sarcoma [192].
Finally, our study offered unexpected technical insights into FAIRE. Previous stud-
ies have noted discrepancies between FAIRE and DNase, particularly at distal regu-
latory elements [102]. However, the biochemical differences characterizing those re-
gions that are enriched by FAIRE but not detected by DNase have not been identified.
Compared with DNase and ATAC, FAIRE-seq seems unique in its ability to identify
unstable nucleosome-bound regions. Resulting from chromatin organizational differ-
ences or histone acetylation, these destabilized nucleosomes may not survive the
biochemical extraction process of FAIRE. In a similar fashion, unstable H2A.Z/H3.3
containing nucleosomes have been found at regions deemed “nucleosome depleted”
[193]. In contrast, DNase and ATAC depend on exposed DNA for enzymatic cleavage.
Consistent with this difference, DNase and ATAC data from Ewing Sarcoma indicates
nucleosome eviction. Nucleosome eviction was also reflected by quantitative gains
in FAIRE signal. Strategies that explore chromatin organization yield distinct insights.
Apparent differences between these methods may indicate specific states that influ-
ence chromatin accessibility.
Overall, we identify a link between stem cell-specific chromatin features at repeti-
tive elements and cancer development. Because of their abundance these elements
may broadly influence nucleosome positioning and chromatin remodeling during dif-
ferentiation. Multiple mechanisms result in variation in repeat element structure and
location. How these factors converge to alter chromatin organization will continue to
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enhance our understanding of development and disease.
2.4 Materials and Methods
2.4.1 Cell Culture and Isolation of BM-MSC
The human embryonic stem cell line H1-ESC, H7-ESC, H9-ESC was obtained
from WiCell Research Institute (Madison, WI). H1 hESC were maintained undifferen-
tiated on 6-well plates coated with growth factor reduced Matrigel (BD Biosciences)
in mTeSR1 media (StemCell Technologies) and the media was changed daily. Cells
were passaged every three days with 0.5mM EDTA.
BM-MSCs were derived from human primary bone marrow (IRB exemption 09-
0127). Media was added to bone marrow and centrifuged at 1500rpm to pellet cells.
Pellet was resuspended and separated using a Ficoll gradient by centrifugation for
30 minutes. Mononuclear cells were collected and washed 1X in PBS. Cells were
resuspended in growth media (DMEM low glucose supplemented with 10% selected
serum) and seeded on plates. After 3-4 days cells were trypsinized, passed through
a cell filter, and incubated with CD11B/MAC-1 (BD Pharmingen #555386) and CD45
(BD Pharmingen #555481). Cells were washed 2X and resuspended with strepta-
vidin coated beads (MACS) according to manufacturer’s recommendations. Cells
were washed 2X and ran through a MS-column (MACS). Negative fraction (Unla-
beled cells) consisting of BM-MSCs was expanded in growth media with twice weekly
media changes.
HKC were maintained in DMEM high glucose supplemented with 10% serum +
1% nonessential amino acids, 1% L-glutamine, 1% pen/strep. Media was changed
every 2 days and cells were passaged 2 times a week.
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2.4.2 Differentiation of H1 MSCs to osteoblasts
H1-MSC were seeded at 6 X 103 cells/cm2 in Mesencult Osteogenic Stimulatory
Kit (StemCell Technologies) and were maintained according to the manufacturer’s in-
structions. Medium was changed every three days and osteogenic differentiation was
visualized using Alizarin Red R staining one month after the beginning of differentia-
tion.
2.4.3 Differentiation of H1 MSCs to adipocytes
H1-MSC were seeded at 5.5 X 105 cells per 10 cm dish or 9.5 X 104 cells/well
of a 6-well plate in StemPro Adipogenesis differentiation kit (Life Technologies) and
were maintained according to the manufacturer’s instructions. The presence of lipid
droplets was confirmed after one month of differentiation using Oil Red O staining.
2.4.4 Flow Cytometry
H1, H1-MSC, and BM-MSCs were stained according to manufacture’s recom-
mended conditions using the BD Stem Flow Human MSC Analysis Kit (#562245).
2.4.5 FAIRE-Seq Analysis
Chromatin from hESC, H1-MSC, and BM-MSC was isolated by fixing cells in 1%
final concentration of formaldehyde for five minutes and quenched using 125mM
glycine. Nuclei were isolated by dounce and sonicated to average fragment size
of approximately 400bp. FAIRE was preformed and sequencing libraries were gener-
ated from DNA enriched by FAIRE and sequenced (Illumina). 50-bp single end reads
were filtered using TagDust (Lassmann et al., 2009) and aligned to hg19 using Bowtie
[160]. FAIRE peaks were called using MACS2 [167]. Default parameters were used
except –shiftsize=67 and –nomodel to better account for the FAIRE fragment length.
To narrow our peak calls to the most confident set, we selected the log10(q-value)
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threshold for the 150,000th peak and selected the regions that were ≥ to that value.
Varying the q-value threshold had no effect on the fraction of peak summits +/− 1bp
that intersected a repetitive element. Data are available from GEO (Accession num-
ber GSE75172). FASTQ files from HUVEC, NHEK, and K562 FAIRE were obtained
from ENCODE and processed as above.
Z-score transformed wiggle files were created using the average FAIRE signal
per base-pair over the genome, excluding chromM and chromY for each sample.
Genome browser shots of representative clusters were visualized using UCSC genome
browser. For quartile analysis average Z-score was found for each repetitive element,
defined be RepeatMasker in the specific class. Repeats were then binned into quar-
tiles and signal plotted for hESCs and differentiated cell types.
The respective repeats in the top quartile of simple repeats and SINEs in hESCs
were selected an intersected between H1-ESC, H7-ESC, H9-ESC. Simple repeats
+/− 500 bp were centered and FAIRE signal plotted. Signal was normalized for reads
per million mapped and log2 transformed. Repeats that were shared among all three
of the ESC were then compared to an equal number of randomly selected repeats
from quartile 1 (FAIRE-negative) for DNA characteristics. G/C content was measured
using KentUtils from ENCODE. FAIRE-enriched (FAIRE +) simple repeats and SINE
were identified by intersecting FAIRE peak summits +/− 1 bp with repetitive elements
defined by RepeatMasker. Normalized FAIRE signal was again plotted around the
repetitive element. For repeat position (Figure 3A) a wiggle file was created where
repetitive regions had scores. This was then plotted to demonstrate the position of the
repeat relative to FAIRE and DNase signals. TSS were downloaded from ENCODE
and CTCF sites were from NHEK cells from ENCODE.
Average FAIRE signal for TSS, CTCF, NANOG, and OCT4 sites were plotted in
H1-ESC, H9-ESC, and H7-ESC (Figure 2.1). CTCF sites were derived from CTCF
Peaks called in NHEK cells from ENCODE. NANOG binding sites were determined by
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peak analysis from H1 ChIP-seq from the ENCODE Consortium. OCT4 binding sites
were determined from peak calls in H9 data previously generated (GEO accession
number GSM545204). Z-scores were used to assay chromatin changes of repetitive
elements during differentiation. Average z-score for each repeat in simple repeats
and SINE was determined. Statistically different repeats were determined between
two groups: H1-ESC, H7-ESC, H9-ESC, and BM-MSC (p-value < 0.01 for SINE and
p-value < 0.05 for simple repeats, t-test). In order to filter out background signal we
required that each repeat pass a z-score threshold (rowmax – rowmin > 3).
2.4.6 DNase-Seq
DNase I hypersensitivity was performed on primary BM-MSC as previously de-
scribed [96] and sequenced (Illumina). Resulting sequencing reads were in-silico
clipped to 20 bp and aligned to the hg19 using BWA. DNase data for H1-ESC was
downloaded from the ENCODE.
2.4.7 Analysis of unaligned reads
Raw sequencing reads that bowtie failed to align to the genome, or were deter-
mined to have multiple mapping sites (m=4) were captured. Reads were then con-
verted into FASTA files. Identical sequences were collapsed and resulting file was
assayed for repetitive elements using RepeatMasker.
2.4.8 Genomic Window Analysis and segmentation
Z-scores were calculated for each nucleotide position excluding chromosomes M
and Y. Scores were then averaged over 500bp non-overlapping windows. Signifi-
cance was assayed between hESCs and HUVEC, NHEK, and K562 by t-test (p-value
< 0.01). To filter out regions of background signal we required that a maximum – min-
imum value > three. Data was clustered using Cluster 3.0 (http://bonsai.hgc.
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jp/˜mdehoon/software/cluster/software.htm) and visualized using Java
Treeview [194] or GENE-E (Website reference : http://www.broadinstitute.
org). Significantly altered windows were then intersected with ChromHMM segmen-
tation coordinates obtained from ENCODE (http://hgdownload.cse.ucsc.edu/
goldenPath/hg19/encodeDCC/wgEncodeBroadHmm) using BEDTools [195]. The
segmentation-based association with the greatest fractional window coverage was
selected for those regions mapping to more than one segmentation. The 15 segmen-
tations patterns were then merged as follows:
Promoters: 1 Active Promoter, 2 Weak Promoter, 3 Poised Promoter Enhancers:
4 Strong Enhancer, 5 Strong Enhancer, 6 Weak Enhancer, 7 Weak Enhancer Insu-
lators: 8 Insulator Transcription: 9 Txn Transition, 10 Txn Elongation, 11 Weak Txn
Repressed: 12 Repressed Heterochromatic/Repetitive/CNV: 13 Heterochrom/lo, 14
Repetitive/CNV, 15 Repetitive/CNV
2.4.9 Segmentation permutation
An equal number of random FAIRE windows was selected from H1 or HUVEC
passing a threshold where at least one sample had a z-score of 3. Regions were
then assigned a classification as before. We conducted 1000 iterations.
2.4.10 Simple repeat and SINE permutation
103,345 of simple repeats and 442,460 SINEs, representing the number found in
a quartile, was randomly selected from all available repetitive elements three times,
representing the three samples. These regions were then intersected, and the shared
regions were calculated. 1000 iterations were conducted.
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2.4.11 Correlation Analysis
The union set of the top quartile of FAIRE signal at simple repeats and SINE
was summed in H1, H7, H9, and HUVEC. Log2 transformed signal was then plotted
against each respective cell type and spearman correlation measured. For TSS and
CTCF, FAIRE and DHS signal was summed +/− 300bp from the center of TSS or
+/− 200bp CTCF. Log2 transformed signal was then plotted against each respective
cell type and spearman correlation measured
2.4.12 Histone modification analysis at repetitive elements
Available H1 histone modifications were downloaded from the Epigenome Roadmap.
Average signal was plotted for FAIRE positive simple repeats and SINE, FAIRE neg-
ative simple repeats and SINE, TSS, and CTCF sites.
2.4.13 RNA-Sequencing and analysis
RNA was isolated from BM-MSCs using Trizol according to manufacturer?s direc-
tions. Ribosomal RNA depletion and preparation for sequencing were performed as
described previously [161]. Sequencing reads were aligned to hg19 using TopHat
[196]. RPKM were calculated and used for comparison against H1-ESC. H1-ESC
RNA-seq data was downloaded from the ENCODE Consortium.
2.4.14 Salt Fractionation
H1-ESCs and HKCs were cultured in normal growth conditions. 10 million cells
were counted using the Bio-Rad TC20 and treated as previously described [175] with
the following modifications. 5 U of MNase I was used to digest nuclei. Extractions
were performed at 40 mM, 80 mM, 160 mM, 320 mM, and 640 mM NaCl in a volume
of 50 µL.
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2.4.15 Salt Fractionation MNase-Seq
Nucleosome protected DNA was isolated from successive treatments of low (160
mM) and high (640 mM) salt as previously described above. Resulting DNA frag-
ments were run on a gel and size excluded from 50-500 bp. DNA was purified using
a gel extraction kit (Qiagen) with slight modification. 6 volumes Buffer QG and 2 vol-
umes of isopropanol were used and samples allowed to dissolve at RT. Purified DNA
was library prepped according to manufacturer’s instructions (Illumina) and paired-
end sequenced.
Paired reads were filtered using TagDust and aligned to the human genome (hg19)
using bowtie with max insertion size of 1000 and Maq rounding disabled. Distribu-
tion of MNase fragment sizes was calculated from paired-read lengths. There are
two peaks clearly shown, indicating the co-existence of mono-nucleosomes and di-
nucleosomes. A wiggle file was created using DANPOS v2.1.3 [197]. DANPOS is
designed mainly for mono-nucleosome MNase-Seq data, so we preprocessed our
sequencing data to account for DANPOS center-weighted mapping for reads from
di-nucleosomes. According to the fragment size distribution (Figure 2.10), fragments
greater than 266 bp were considered from di-nucleosomes and others were from
mono-nucleosomes. The empirical distribution of mono-nucleosomes was estimated
and used to simulate the fragment length when splitting di-nucleosomes into mononu-
cleosomes in silico. After preprocessing, the fragment size distribution meets the as-
sumption of DANPOS. The resulting wiggle file was used to plot nucleosome density
at simple repeats.
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CHAPTER 3
PTEN DEFICIENCY MEDIATES RECIPROCAL RESPONSE TO IGF1 AND MTOR
INHIBITION1
3.1 Introduction
Ewing sarcoma is a malignant bone and soft tissue tumor primarily affecting chil-
dren and young adults. Despite intensive chemotherapy, surgery and radiation ther-
apy approximately 50% of patients ultimately succumb to the disease. Ewing sar-
coma is characterized by chromosomal translocations that fuse a member of the TET
family to one of a subset of ETS transcription factors [103][77]. Eighty to eighty-five
percent of Ewing Sarcoma tumors contain t(11;22)(q24;q12) generating an in-frame
fusion of EWSR1 to FLI1[77]. The resulting chimeric EWS-FLI1 protein is a potent
transcriptional modulator that regulates multiple genes implicated in malignant trans-
formation [92][94].
Several lines of evidence support a role for the insulin-like growth factor (IGF) path-
way in the development of Ewing sarcoma. EWS-FLI1 regulates IGF1 in Ewing sar-
coma cell lines and is induced by EWS-FLI1 in mesenchymal stem cells [90][104][105].
IGF-1 and its receptor (IGF-1R) are expressed in tumors, and IGF-1 expression in
cell lines leads to autocrine activation [106][107]. IGF-1 signaling is necessary for the
1This chapter previously appeared as an article in Molecular Cancer Research. The original citation
is as follows: Patel M, Gomez NC, McFadden AW, Moats-Staats BM, Wu S, Rojas A, Sapp T, Simon
JM, Smith SV, Kaiser-Rogers K, Davis IJ. PTEN deficiency mediates a reciprocal response to IGFI and
mTOR inhibition. Mol Cancer Res. 2014 Nov;12(11):1610-20.
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survival and proliferation of Ewing sarcoma cells [108][109], transformation of murine
fibroblasts by EWS-FLI [110] as well as for normal bone development [111]. The
promising results of preclinical trials targeting IGF pathway in Ewing Sarcoma has
made it an attractive therapeutic target [112][113][114][115]. However, studies of IGF-
1 and IGF-1R inhibitors in early phase clinical trials have shown a limited response
rate [116][117][118]. A biomarker predictive of individuals who may respond to IGF1-
mediated treatment remains to be identified [119][120]. IGF-1 bound to IGF-1R ini-
tiates a signaling cascade through the PI3K pathway resulting in phosphorylation of
downstream targets including AKT. Phosphorylation of AKT at serine-473 (S473) and
threonine-308 (T308) promotes cell cycle progression, cell survival, migration, and
metabolism through differential interactions with multiple substrates including mTOR
[121][122]. Signaling through the PI3K pathway is attenuated by PTEN through de-
phosphorylation of PIP3[123]. The loss of PTEN results in increased accumulation
of PIP3 and AKT activation, which has been associated with poor clinical outcomes
[124][125][126]. The loss or mutation of PTEN has been demonstrated in a range of
cancers [124][125][126][127][128]; however, the function of PTEN in Ewing sarcoma
has yet to be investigated. Here we describe PTEN loss in Ewing sarcoma and its
consequences on IGF and mTOR signaling, as well as on biochemical responses to
small molecule inhibitors. PTEN deficiency augments PI3K signaling to AKT while
diminishing cellular responsiveness to IGF inhibition. Interestingly, PTEN loss en-
hances sensitivity to autophagy induced by mTOR inhibition. Together these data
suggest how PTEN loss may influence the response to biological therapies in Ewing
sarcoma.
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3.2 Materials and Methods
3.2.1 Fluorescent In Situ Hybridization
The RP11-383D9 (D9) and RP11-846G17 (G17) BACs were obtained from the
Children’s Hospital Oakland Research Institute. Bacterial cultures of both BACs were
grown in LB with 25 µg/mL chloramphenicol and DNA extracted using Qiagen Plas-
mid Midi Kit with slight modifications (10 mL of Buffer P1, P2, and P3 and DNA was
eluted in 1 mL increments using prewarmed Buffer QF at 65◦C). Probes were made
using 1 µg of BAC DNA by nick translation (Abbott Laboratories, cat #32-801300)
with Red-dUTP (Abbott, cat # 02N34-050) according to manufacturer’s protocol. A
Chromosome 10 centromeric probe (CEP, Abbott Laboratories) was used as a con-
trol. Cell lines were trypsinized, washed, and then resuspended in a small volume
of PBS. 10 mL of KCl at 37◦C was added dropwise with gentle agitation for the first
2 mL. After adding KCl, the solution was mixed and placed in a 37◦C water bath for
12 min after which 1 mL of fresh cold 3:1 methanol:acetic acid (fixative) was added.
Cells were collected by centrifugation (10 min, 1000 RPM) and the pellet was resus-
pended in 10 mL of fresh cold fixative which was added dropwise with gentle agitation
for the first 2 mL and incubated at room temperature for 10 min. This process was
repeated twice. BAC and CEP probes were then hybridized to each cell line before
imaging. PTEN and CEP signals were manually counted from at least 20 nuclei in
five separate fields.
3.2.2 Cell culture and Antibodies
Unless otherwise indicated, EWS502, EWS894, and RD-ES cell lines were cul-
tured in RPMI supplemented with 15% fetal bovine serum. A673 and MHH-ES-1
cell lines were cultured in RPMI supplemented with 10% fetal bovine serum. SK-ES
cells were cultured in McCoy’s 5A supplemented with 15% fetal bovine serum. SK-N-
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MC cells were cultured in DMEM supplemented with 10% fetal bovine serum, 2 mM
L-glutamine and 1X nonessential amino acids. EWS502 and EWS894 were kindly
provided by Dr. Jonathan Fletcher (Brigham and Women’s Hospital, Boston) and
A673 by Dr. Stephen Lessnick (Univ. of Utah). Other cell lines were obtained from
the DSMZ (Braunschweig, Germany). HUVEC cells (Lifeline Technologies) were cul-
tured in Vasculife Basal Media (Lifeline Technologies) supplemented with 10% FBS.
CD99 (clone 12E7, Ready-to-use, PA0559, Leica Microsystems) and PTEN antibod-
ies (clone 138G6, 9559S, Cell Signaling Technology) were used for IHC and IF. AKT
(#4691), pAKT T308 (#2965), pAKT S473 (#4060) and LC3B (#3868), cleaved PARP
(#5625) were used for immunoblotting (Cell Signaling Technology).
3.2.3 Cell Proliferation, Apoptosis, Soft agar, and Autophagy
pLL5.0-PTEN (which expresses PTEN), pLL5.0-shPTEN (which expresses an
shRNA directed at PTEN 5’-GTATAGAGCGTGCAGATAG-3’) and pLL5.0-shNS (which
expresses a non-specific shRNA as a control) were kindly provided by Dr. James
Bear (UNC-Chapel Hill). Lentivirus was produced as previously described [129].
EWS502 cells were transduced with either pLL5.0-PTEN or vector control lentivirus
in the presence of polybrene (6 µg/mL) for 3 hours, after which media was changed
and the cells split for proliferation, soft agar assays. Cells were stained with trypan
blue and counted using a hemocytometer to assay proliferation. For soft agar, 0.6%
agar was used as the base layer and 0.5% agar as the top layer. The plates were
counted manually using ImageJ (NIH). Apoptosis was assessed using the Annexin
V-Cy3 Apoptosis Detection Kit (Sigma-Aldrich) according to the manufacturer’s pro-
tocol. Flow cytometry was performed using the CyAn ADP (Beckman-Coulter). For
assessment of autophagy, three days after lentiviral transduction A673 and EWS502
cells were split 1:3 and treated with 20 µM chloroquine for 3 hours or chloroquine
followed by 10 ng/mL temsirolimus (LC Laboratories) for 20 hrs. Cells were lysed in
49
CHAPS buffer and extracts were separated by SDS-PAGE.
3.2.4 IGF-1 inhibition
Cells were treated with NVP-AEW541 (Cayman Chemical) and OSI-906 (ChemieTek)
at the indicated concentrations. Prior to treatment with IGF-1, cells were kept in
serum-free media for two hours in combination with the IGF-1 inhibitor. Cells were
then treated with IGF-1 (Cell Signaling Technologies) for 15 min and lysed in RIPA
buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 0.1% SDS) supplemented
with 200 mM NaVO4 and 50 mM NaF. Cell extracts were separated by SDS-PAGE
and blotted with anti-phospho AKT and imaged (LiCor). For assessment of cell vi-
ability, EWS502 cells were transduced with lentiviral pLL5.0-PTEN or pLL5.0 as a
vector control. 24 hours post infection the cells were treated with NVP-AEW541 in
complete media. Viability was assayed 72 hours following NVP-AEW541 treatment
using WST-1 (Roche).
3.2.5 Tissue microarray (TMA) and Cell Line Array (CLA) construction
Pellets from the Ewing sarcoma cell lines were fixed in 10% buffered formalin
(SF98-4, Fisher Scientific) for 16-24 hours, washed twice in 70% ethanol, clotted in
2% low-melting agarose (Fisher), and then embedded in paraffin wax. Blocks were
sectioned and stained with hematoxylin and eosin (H&E, Hematoxylin 7211, Eosin
7111, Richard-Allan). Three 1 mm cores were removed and embedded into recipient
CLA block. For TMA construction, Ewing sarcoma cases (n = 25) and controls (breast
carcinoma, and PTEN-deleted sarcoma) were selected from The University of North
Carolina Surgical Pathology and St. Jude Children’s Research Hospital archives un-
der an IRB-approved protocol. Hematoxylin and eosin (H&E) stained slides were
re-reviewed and representative areas of tumor were marked for coring. TMA blocks,
containing triplicate 0.6 mm cores per case were constructed. TMA and CLA blocks
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were cut into 4 and 5 micron sections respectively and placed on positively charged
glass slides.
3.2.6 Immunohistochemistry (IHC) and Immunofluorescence (IF)
TMA and CLA slides were stained with CD99 and PTEN antibodies (Bond fully-
automated slide staining system, Leica Microsystems). Slides were deparaffinized
(Bond, AR9222) and hydrated in wash solution (Bond, AR9590). Epitope retrieval
(pH 9.0, AR9640, Bond) was performed followed by a peroxide blocking step (Bond
DS9800). CD99 and PTEN (1:400) antibodies were incubated for 15 and 30 minutes,
respectively then secondary antibody was applied (polymer, Bond DS9800). Chro-
mogenic detection with 3,3’-diaminobenzidine (DAB) and hematoxylin was performed
(Polymer Refine Detection, DS9800, Bond). Stained slides were dehydrated and
mounted. For fluorescent detection, the TSA-Cy5 reagent (PerkinElmer), Hoechst
33258 (Invitrogen) and ProLong Gold antifade reagent (Molecular Probes) were used.
3.2.7 Imaging and digital image analysis
IHC stained TMA sections were digitally imaged (Aperio ScanScope XT, Ape-
rio Technologies). High-resolution DAPI and Cy5 IF images were obtained (Aperio
ScanScope FL). For digital images from IHC slides, Aperio’s Cytoplasmic algorithm
was used to determine the percentage and intensity of cells positive for PTEN or
CD99. A PTEN-deleted tumor control was used to set the negative/low positive in-
tensity threshold for the PTEN stained TMA slide. IF signal was quantified (Definiens
Tissue Studio, version 3.6).
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3.3 Results
3.3.1 A subset of Ewing Sarcomas lack PTEN
We recently reported widespread alterations in chromatin structure and histone
modifications in Ewing sarcoma cells using high-throughput sequencing [90]. Al-
though the experiments performed were intended to detect nucleosome-depleted re-
gions of chromatin, background signal from Formaldehyde Assisted Isolation of Regu-
latory Elements (FAIRE-seq) typically covers the remainder of the genome mappable
by short sequencing read and thus offers a genome-wide sampling of DNA content.
Unexpectedly, we observed an approximately 1 Mb region on chromosome 10 that
demonstrated a nearly complete loss of FAIRE-seq signal, which we hypothesized
to indicate homozygous deletion (Figure 3.1 A). The potential deletion encompassed
several genes including the terminal exons of PTEN (Figure 3.1 A).
Since deletion of PTEN had yet to be detected in Ewing sarcoma using high
throughput sequencing approaches, we verified this deletion by fluorescence in situ
hybridization (FISH) using two probes that overlap the PTEN locus, as well as a con-
trol centromeric probe. One probe (G17) is fully contained within the deleted region
whereas half of the second probe (D9) was predicted to hybridize outside the deletion
(Figure 3.1 A). Probes were hybridized to seven Ewing sarcoma cell lines (EWS502,
EWS894, A673, MHH-ES-1, SK-ES, RD-ES-1, SK-N-MC) and one control cell line
(HUVEC). The absence of signal from the G17 probe in EWS502 cells confirmed a
homozygous deletion at this region (Figure 3.1 B). Signal from the D9 probe was de-
tected which likely results from hybridization to the retained region centromeric to the
deletion. Signal was observed for both probes in the other Ewing sarcoma and control
cell lines. However, EWS894 and SK-N-MC cells exhibited PTEN/centromeric probe
ratios not equal to one suggesting other cytogenetic aberrations involving the long
arm or centromere of chromosome 10 (Figure 3.1 B, C). EWS894 had two copies
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Figure 3.1: Identification of PTEN deletion in Ewing Sarcoma. A) FAIRE-seq derived
high throughput sequencing tag density around the PTEN locus in EWS502. Red
bars indicate the regions of hybridization for the FISH probes. Only genes located
within the deletion are shown. B) PTEN FISH for representative Ewing sarcoma cell
lines and a control (HUVEC). Chromosome 10 centromeric probe (green) and PTEN
BAC probes (red) are shown. C) Observed ratio of PTEN probe to centromeric probe
(CEP) signal. Error bars indicate standard deviation of PTEN/CEP probe ratio from
five unique fields counting a minimum of 20 cells per field (with the exception of SK-
ES in which 20 nuclei were analyzed). D) Immunoblot of PTEN in Ewing sarcoma
cells. Extracts of EWS502, EWS894, A673, MHH-ES-1, SK-ES, RD-ES, and SK-N-
MC and a control cell line, HUVEC were blotted with anti-PTEN antibody. Tubulin was
used as a loading control.
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Figure 3.2: MHH-ES-1 and RD-ES are triploid for chromosome 10. Interphase nuclei
of indicated cell lines were hybridized with two BACS (D9 and G17) targeted to the
PTEN locus (red) and centromeric probe (green).
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Figure 3.3: Sections of the Ewing sarcoma tissue microarray were hybridized with
D9 and G17 PTEN BACS as well as a chromosome 10 centromeric control (CEP).
The PTEN/centromeric ratio is plotted. Breast cancer (+ control) and undifferentiated
sarcoma (− control) are shown.
of the PTEN locus but three copies of the centromeric probe whereas one copy of
the PTEN locus and two copies of the centromeric probe were detected in SK-N-MC.
The PTEN/centromeric probe ratio was equivalent for the remaining cell lines; MHH-
ES-1 and RD-ES exhibited triploidy of chromosome 10 (Figure 3.2). Consistent with
PTEN chromosomal loss, PTEN protein was absent in EWS502 whereas other Ewing
sarcoma cell lines showed variable levels (Figure 3.1 D).
In order to address whether PTEN was similarly lost in primary Ewing sarcoma
tumor, we generated a tissue microarray consisting of 25 tumors diagnosed as Ew-
ing Sarcoma during clinical evaluation. The samples were re-reviewed prior to mi-
croarray generation, and tumor-specific regions were selected for core preparation.
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Each tumor was represented in triplicate at random positions on the array. Microarray
sections were hybridized to both FISH probes. For the 20 tumors from which FISH
signal was interpretable, homozygous loss was not observed however copy num-
ber varied across tumors (Figure 3.3). Since PTEN expression can be affected by
mechanisms other than deletion, we analyzed PTEN protein levels by immunofluo-
rescence (IF) and immunohistochemistry (IHC). A Ewing sarcoma cell line array was
generated to validate antibody-mediated detection of PTEN. PTEN detection by IHC
and IF on the cell line array quantitatively matched detection by Western blotting (r2
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Figure 3.4: PTEN immunofluoresence is concordant with immunoblotting. Immunoflu-
orescence for PTEN was performed on the CLA with anti-PTEN antibody and quan-
tified. Extracts of each cell line were separated by SDS-PAGE, immunoblotted with
anti-PTEN antibody and quantified. The average H-score was plotted against the cor-
responding immunoblot quantification normalized to tubulin (arbitrary units). Best fit
line is shown.
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= 0.74, Figure 3.4). Because of the diverse age of the samples that contributed to
the primary tumor array and the evolving criteria for Ewing sarcoma diagnosis, we
performed IHC and IF for CD99 as confirmation of diagnosis and as a quality control.
IHC and IF for CD99 as well as PTEN were highly concordant (Figure 3.5). After
eliminating CD99 negative tumors and those with poor staining 15 tumors remained.
A wide range of PTEN expression was detected by IF among the Ewing sarcoma
samples. Three tumors demonstrated significantly reduced signal when compared to
a PTEN-expressing control breast carcinoma sample and a PTEN-deficient undiffer-
entiated sarcoma (Figure 3.6 A). Histological examination suggested that non-tumor
cells confounded accurate PTEN quantification. We attempted IF for CD99 to specif-
ically identify tumor cells, but due to technical constraints co-staining of PTEN and
CD99 was not possible. However, using CD99 IHC in adjacent sections, we con-
firmed the IF results. We observed that for one additional tumor (tumor 2, Figure 3.6
A and B) 55% of the cells did not demonstrate PTEN signal (Figure 3.7). Remaining
PTEN expression in this sample may be related to CD99-negative non-tumor cells or
tumor heterogeneity (Figure 3.6 B). These data suggest that PTEN expression is re-
duced in approximately 25% (4 of 15) of Ewing sarcomas, and that the loss of PTEN
is primarily through mechanisms other than large genomic losses. This observation
is consistent with other tumors in which PTEN expression is lost due to gene silencing
or focal deletions [130][131][132][133](32-35).
3.3.2 PTEN loss in Ewing sarcoma augments AKT signaling
To determine the effect of PTEN loss on AKT signaling across Ewing sarcoma
cell lines we examined phosphorylation at S473 and T308. Phosphorylation of these
sites is indicative of AKT activation [121][122]. Among the cell lines tested, EWS502
had the highest level of pAKT (Figure 3.8 A). Low levels of S473 phosphorylation
was also observed in EWS894, SK-ES, and RD-ES-1 cells. T308 phosphorylation
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was plotted.
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averaged. The percentage of cells of each score was plotted.
was limited to EWS502. PDK1-associated phosphorylation of T308 is associated
with full AKT activation [134][135] and was only observed in the absence of PTEN
suggesting that AKT activation is augmented by PTEN loss. We then ectopically
expressed PTEN in EWS502 cells to test the association between PTEN levels and
activated AKT. Increasing PTEN was associated with a progressive decrease in pAKT
at S473 and T308 (Figure 3.8 B) suggesting that AKT activation in EWS502 is due
in part to PTEN deficiency. To test whether PTEN loss altered IGF-1 sensitivity, we
examined dose-dependent stimulation by IGF-1 under serum-free conditions. AKT
demonstrated baseline phosphorylation in all Ewing sarcoma cell lines. IGF-1 stim-
ulation resulted in further AKT activation. However, there was no difference in IGF-1
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IC50 (Figure 3.9). These data indicate that PTEN levels influence AKT activation but
do not result in enhanced sensitivity to IGF-1.
The cellular effects of PTEN loss in Ewing sarcoma were examined by testing the
effect of PTEN on cellular proliferation and anchorage-independent growth. PTEN
was transduced into EWS502 cells and expression was confirmed by immunoblotting.
PTEN expression resulted in significantly decreased cellular proliferation (Figure 3.8
C). To address whether the reduction in cell proliferation following PTEN expression
could be attributed to increased apoptosis, we assayed annexin V reactivity by flow
cytometry and observed a significant increase relative to control cells (Figure 3.8 D).
We also observed a similar increase in cleaved PARP (Figure 3.10). Anchorage-
independent growth as assayed by colony formation in soft agar was also greatly
diminished (Figure 3.8 E). Taken together, these data demonstrate that PTEN loss
enhances cellular properties associated with transformation in Ewing sarcoma cells.
3.3.3 PTEN loss decreases sensitivity to IGF-1 inhibition
Since clinical trials of IGF-1-targeted inhibitors have demonstrated robust but lim-
ited patient responses, we asked whether PTEN loss might mitigate the effect of
these compounds in Ewing sarcoma cells. Ewing sarcoma cells were treated with
two IGF-1R inhibitors, NVP-AEW541[136] and OSI-906 [137]. NVP-AEW541 has
been tested for Ewing sarcoma whereas OSI-906 is an investigational agent for a
variety of cancers [113][114][137][138][139][140]. Cells cultured in serum-free media
were pretreated with these inhibitors prior to stimulation by IGF-1. PTEN loss was
associated with increased IC50 to the IGF-1 inhibitors as measured by AKT activa-
tion (Figure 3.11 A). This differential sensitivity was detectable by phosphorylation at
both S473 and T308. Interestingly, intermediate sensitivity to these inhibitors was
observed for EWS894 and SK-ES, both of which demonstrated lower PTEN levels
and detectable pAKT-S473. We then examined the effect of PTEN expression on
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Figure 3.8: PTEN loss enhances AKT signaling promoting transformation. A) Im-
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growth conditions were immunoblotted for phospho-AKT at S473 and T308. B)
PTEN expression abrogates phospho-AKT. EWS502 were transduced with increas-
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IGF-1R inhibition focusing on NVP-AEW541 due to its selectivity for IGF-1R [136].
Transduced PTEN resulted in enhanced sensitivity for NVP-AEW541 with an IC50
approximating the other PTEN-expressing Ewing sarcoma cells (Figure 3.11 B). The
enhanced sensitivity for NVP-AEW541 was associated with increased cellular toxicity
(Figure 3.11 C). These data suggest that PTEN loss in Ewing sarcoma diminishes
the efficacy of IGF-1R inhibitors on PI3K signaling as well as viability.
3.3.4 PTEN loss enhances response to temsirolimus
AKT signaling acts on the mTOR pathway to influence multiple cellular processes
including autophagy [141][142]. In light of the emerging role of mTOR inhibition in
Ewing sarcoma treatment, we examined the relationship between PTEN loss and au-
tophagic response to the mTOR inhibitor, temsirolimus. Ewing sarcoma cells were
treated with temsirolimus and autophagy was assayed by quantification of LC3BII, a
protein localized to autophagosome membranes that is generated during autophagy
[143]. The assay was performed in the presence of chloroquine to inhibit lysosomal
processing and thus enable assessment of autophagy without ongoing degradation.
PTEN-expressing Ewing sarcoma cells (A673) demonstrated minimal LC3BII induc-
tion in response to chloroquine or to chloroquine and temsirolimus (Figure 3.12 A).
In contrast, EWS502 cells demonstrated a modest induction of LC3BII in response
to chloroquine, but this response was significantly increased by temsirolimus (Figure
3.12 B). Since EWS502 but not A673 cells demonstrated induction of temsirolimus-
induced autophagy, we examined the effect of modulating PTEN. Silencing PTEN in
Figure 3.9: IGF-1 sensitivity is not influenced by the presence of PTEN. Cell lines
were serum starved for two hours followed by treatment with IGF-1 treatment at the
indicated concentrations for 15 min. Cells were lysed, immunoblotted for pAKT and
quantified. Phospho-specific signals were normalized to total AKT. A) Quantification
of phospho-T308 and phospho-S473 are shown. B) Fold induction for phosphor-T308
and phospho-S473 was calculated relative to the maximum.
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A673 cells augmented the autophagic response to temsirolimus whereas exogenous
PTEN expression in EWS502 eliminated the effect of temsirolimus (but not chloro-
quine) (Figures 3.12 A and B). We then examined the effect of inhibiting autophagy
with chloroquine on cellular viability. Interestingly, treatment with chloroquine atten-
uated the toxic effects of temsirolimus in the absence of PTEN but this difference
was lost when PTEN was expressed. (Figure 3.13). Together these experiments
demonstrate that PTEN expression in Ewing sarcoma cells influences autophagic re-
sponse to temsirolimus with PTEN loss associated with increased responsiveness to
mTOR inhibition. Further, the induction of autophagy by temsirolimus is associated
with decreased viability, suggesting that autophagy partially mediates the effects of
temsirolimus.
3.4 Discussion
The unexpected identification of PTEN deletion in a Ewing Sarcoma cell line led us
to explore the status of PTEN in primary tumors. Although we were unable to detect
a similar deletion in other cell lines or a set of primary tumors using FISH, quantitative
assessment of PTEN expression by IHC and IF suggested that approximately 25%
Figure 3.11: PTEN modulates sensitivity to IGF-1R inhibitors. A) PTEN loss de-
creases sensitivity to IGF-1R inhibitors. Ewing Sarcoma cells were treated with NVP-
AEW541 (left) or OSI-906 (right) at the indicated concentrations for 2 hours in serum-
free media and then stimulated with IGF-1 (5 ng/mL final concentration) for 15 min.
Extracts were immunoblotted for pAKT at Thr 308 (top) and S473 (bottom) and re-
sults were quantified. Relative inhibition was calculated by normalizing pAKT signal
to mock treatment (zero concentration). B) PTEN expression increases sensitivity to
IGF-1R inhibition. EWS502 transduced with PTEN (dotted grey) or a control vector
(solid black) were exposed to NVP-AEW541 for 2 hours in serum-free media and then
stimulated with IGF-1 (5 ng/mL final concentration) for 15 min. Relative inhibition was
calculated as above. C) PTEN expression increases the cellular toxicity associated
with NVP-AEW541 treatment. EWS502 cells were transduced as in B and treated
with NVP-AEW541 for 72 hours at indicated concentrations and assayed for viabil-
ity. For each panel, error bars represent standard error between replicates. · and ··
indicate p < 0.05 and p < 0.01 respectively (two-tailed T-test).
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of Ewing sarcoma tumors are PTEN deficient. Small deletions and other mutations
undetectable by FISH, in addition to gene silencing, remain alterative mechanisms
that result in PTEN loss in Ewing sarcoma. However, our observation of PTEN loss
is consistent with a recent study that used high resolution SNP arrays to examine
copy number variation in Ewing sarcoma and observed PTEN deletion in 14% of the
tumorsLynn:2013gy. We found that PTEN deficiency leads to enhanced AKT acti-
vation associated with decreased apoptosis, increased proliferation, and anchorage-
independent growth. Enhanced properties associated with cellular transformation in
Ewing sarcoma could result in a more aggressive tumor phenotype. Intriguingly, ETS
deregulation may cooperate with PTEN loss to accelerate tumorigenesis [144]. Sev-
eral lines of evidence indicate that mTOR contributes to PTEN-dependent negative
feedback regulation of AKT (reviewed in [145][146]). The loss of PTEN in Ewing sar-
coma may be one mechanism mediating hyperactivation of AKT even in the absence
of growth factors such as IGF-1. In addition to potentially contributing to a more
transformed phenotype, hyperactivation of AKT may decrease sensitivity of Ewing
sarcoma cells to chemotherapy [147][148].
We have demonstrated that loss of PTEN decreases sensitivity to IGF-1R inhi-
bition, as measured by AKT phosphorylation. Of the limited number of available
cell lines tested, there were varying degrees of response to IGF-1R inhibition. An
intermediate effect was seen in two cell lines with reduced PTEN expression and
increased AKT phosphorylation. These findings are consistent with a prior study
demonstrating that PTEN silencing in cultured glioblastoma decreased response to
NVP-AEW541[149].
PTEN loss led to increased sensitivity to temsirolimus treatment as marked by the
activation of autophagy. Autophagy is a metabolic recycling process in which cellular
components are broken down in times of stress to maintain metabolic homeostasis.
The role of autophagy in cancer is complex. Our results suggest that autophagy is re-
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Figure 3.12: PTEN loss potentiates temsirolimus-induced autophagy. A) PTEN si-
lencing enhances induction of autophagy in response to temsirolimus. A673 cells
transduced with a PTEN-shRNA (shPTEN) or nonspecific control (shNS) were treated
with chloroquine (CQ) alone or chloroquine and temsirolimus (10 ng/mL) for 20 hours
(CQ/TM). Chloroquine was added 3 hours prior to the initiation of temsirolimus treat-
ment. Cell extracts were immunoblotted for LC3B, PTEN, and tubulin (top). LC3BII
bands were quantified and normalized to tubulin (bottom). B) PTEN expression ab-
rogates induction of autophagy in response to temsirolimus treatment. EWS502 cells
transduced with exogenous PTEN or a control vector (GFP) were treated with chloro-
quine (CQ) alone or chloroquine and temsirolimus (10 ng/mL) (CQ/TM) as described
above. Cell extracts were immunoblotted and quantified as above. · and ·· indicate p
< 0.05 and p < 0.01 respectively by two-tailed T-test.
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quired to mediate the cell viability effects of mTOR inhibition by temsirolimus. These
data are in agreement with studies indicating that induction of excessive autophagy
can lead to cell death [150][151]. mTOR inhibitors may constitute a promising ther-
apeutic class for cancers lacking functional PTEN by inducing autophagy-mediated
apoptosis.
PTEN deficiency renders cells less sensitive to IGF-1R inhibition but increases au-
tophagic response to mTOR inhibition. The differential response to AKT/mTOR path-
way manipulation has therapeutic implications. The promise of personalized therapy
for cancer depends on the identification of genetic alterations in specific tumors. The
limited efficacy of IGF-1R inhibition offers an opportunity for the application of rel-
evant biomarkers. Our results indicate that loss of PTEN expression may diminish
the therapeutic response of Ewing sarcoma to IGF-1R inhibitors. However, our study
also suggests a reciprocal interaction between PI3K/AKT signaling and autophagy.
Whereas PTEN loss decreased sensitivity to IGF-1R inhibition, it enhanced sensitiv-
ity to temsirolimus. These data suggest that patients who are unresponsive to IGF-1R
inhibition may benefit from mTOR inactivation. The application of PTEN expression
as a biomarker to future clinical trial would be needed to directly assess this possi-
bility. Due to interactions between the IGF-1R and mTOR pathways, combination of
IGF-1R- and mTOR-directed therapies are being evaluated in preclinical and early
phase clinical trials with evidence of efficacy [152][153][154][155]. The ability to iden-
tify and apply relevant prognostic biomarkers during the selection of biologically active
therapies may greatly increase the possibility of therapeutic benefit.
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CHAPTER 4
CONCLUSIONS AND FUTURE DIRECTIONS
We had originally intended to assay the chromatin changes that accompany differ-
entiation, but were surprised to find a previously unreported widespread enrichment
of repetitive elements in stem cell chromatin. Following up on this observation, we
confirmed that two classes of repetitive elements, simple repeats and SINEs, were
significantly enriched in FAIRE-positive chromatin of three independent hESC lines.
We demonstrated that FAIRE-positive repetitive elements are marked by acetylated
histones and associated with genes involved in lineage specific developmental path-
ways. The high concordance of signal across three cell lines, and specific histone
acetylation enrichment suggests that these regions are playing a role in general stem
cell biology. Though, acetylation have previously been shown to be important for
maintaining pluripotency, these studies have generally focused on pan acetylation
[210][211]. These data, coupled with the our observation of repetitive element chro-
matin closing during differentiation, suggests an intriguing hypothesis that open chro-
matin at repetitive elements is necessary for the multipotency of these cells. Treating
hESC with inhibitors targeting the specific HATs responsible for the acetylation found
at repetitive elements could lead to more condensed chromatin resulting in sponta-
neous differentiation. Alternatively, the condensed chromatin environment could have
the opposite effect and reduce the efficiency of differentiation, suggesting that the
chromatin environment at these repetitive elements are important for downstream de-
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velopmental processes. Regardless of the outcome, these experiments represent a
targeted approach to interrogate the importance of specific histone acetylation marks
and repetitive elements in hESC physiology.
We demonstrated chromatin remodeling at repetitive elements during differenti-
ation of hESC to MSCs. Both, in-vitro differentiated MSCs and primary BM-MSC
retained chromatin accessibility at repetitive elements. However, HUVECs and other
differentiated cell types lacked FAIRE signal suggesting that these regions are fur-
ther remodeled during terminal differentiation. To answer this hypothesis, we have
begun to assay chromatin accessibility in primary adipose tissue to identify the sta-
tus of repetitive elements of in-vivo terminally differentiated cells. Through a special
collaboration with a surgeon at UNC, we have received excess adipose tissue from
surgical discards. I then dissociate the tissue using collagenase, isolate and purify
the adipocytes through centrifugation. Due to the low density of lipids, adipocytes
float as a layer of cells after centrifugation. We can then isolate a pure population
of adipocytes and perform FAIRE-seq specifically looking at chromatin accessibility
of repetitive elements. Currently, we are attempting to optimize the parameters of
FAIRE for this cell type.
Both hESCs and BM-MSCs demonstrated chromatin accessibility at repetitive ele-
ments suggesting a signature for multipotency and stemness. Recently, Yamanaka et
al. were able to “reprogram” terminally differentiated cells by exogenously expressing
a set of four transcription factors [212][213]. These cells reverted to a more stem-like
state having the ability to differentiate into cells from the three germ-layers, as well
as form chimeric mice, leading to the term induced pluripotent stem cells (iPSCs)
[212]. Therefore, we hypothesize that iPSCs undergo chromatin remodeling resulting
in accessibility at repetitive elements. Assaying iPSC chromatin, using FAIRE-seq, at
various stages during reprogramming would give insight into repetitive element chro-
matin remodeling. Couple these experiments with RNA-seq, and we could identify
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the specific chromatin remodelers that are activated at the time point when repetitive
elements become accessible, providing biological insight into how and when these
regions are remodeled. Further, inhibition of the identified remodeler(s) using an in-
ducible CRISPR knockout, would allow us to determine if chromatin remodeling at
these regions is necessary for complete reprogramming. Taken together, iPSCs are
an excellent model to understand repetitive element remodeling from the perspec-
tive of reprogramming into a stem cell as would add further evidence for repetitive
element accessibility as a signature of stemness.
Consistent with other studies, our results suggest that the chromatin environment
at repetitive elements is influencing gene expression [214]. We hypothesize that the
repetitive element itself is crucial for this activity. To test this, we would delete specific
repetitive elements using site specific CRISPR and assay RNA and protein with RT-
qPCR and immunoblotting respectively, in knockouts and wild-type. Additionally, we
could prevent the acetylation of these elements by targeting the specific HATs using
RNAi or CRISPR techniques. Both of these approaches would help elucidate the
role of repetitive elements in gene expression. Ultimately, the term “junk” DNA is
rapidly being debunked and repetitive elements likely have functional significance
within the human genome. In fact, evidence from our lab and others have previously
demonstrated the repetitive elements can serve as transcription factor binding sites
as well as act as enhancer elements, suggesting an importance in other cell types
including cancer [90][215][216].
Though the origin of Ewing sarcoma continues to be debated, our results suggest
a stem-like precursor. Strikingly, both BM-MSCs and Ewing Sarcoma demonstrated
a marked similarity in enrichment of chromatin accessibility at a subset of simple
repeats important for EWSR1-FLI1 targeting. These results are one of the first to
demonstrate similarities in the chromatin environment between MSCs and Ewing sar-
coma and add to the growing evidence suggesting MSCs as the cell of origin for this
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disease. However, our results have not definitively ruled out a neuronal precursor.
In fact, we hypothesize that a neuronal precursor would also have increased chro-
matin accessibility at repetitive elements leading to oncoprotein retargeting. It would
be beneficial for future experiments to assay chromatin accessibility of repetitive el-
ements in these cell types. In addition, using ChIP-seq to assay binding sites of
EWSR1-FLI1 in neuronal cells, may demonstrate a significant overlap in binding sites
with BM-MSCs. It may be that both sides of the debate are correct, and Ewing sar-
coma arises after a translocation in either neuronal or mesenchymal stem cells due
to the permissive chromatin environment.
Though we noted an enrichment of FAIRE signal at all GGAA in BM-MSC, those
regions that had increased signal in BM-MSCs tended to be the the ones that were
targeted by EWSR1-FLI1 in the cancer (Figure 2.14). The repeats targeted by EWSR1-
FLI1 also demonstrated a mild enrichment in acetylated histones relative to non-
targets. This suggests that a subset of these regions in BM-MSCs are primed for
exploitation of the fusion protein. Further studies will need to be conducted in or-
der to understand why these specific regions are targeted. Repetitive elements have
been demonstrated to form alternative DNA structures. One hypothesis is that these
regions share a common structure that distinguishes them from non-targeted regions.
Previous studies have determined that 10-14 (GGAA) motifs are required for optimal
EWSR1-FLI1 binding [90]. Perhaps these regions form an alternative DNA structure
that is recognized by EWSR1-FLI1, and those regions having more or less motifs
do not properly form the correct structure. Using algorithms designed to identify al-
ternate structures, we could look for differences between EWSR1-FLI1 bound and
unbound GGAA repeats.
In addition to Ewings, many other sarcomas, such as liposarcomas, alveolar sar-
coma, and chondrosarcoma, are characterized by the presence of translocations cre-
ating novel transcription factors [66]. A fundamental question remaining is if these
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translocations are similarly retargeted away from their canonical motif. Using bioin-
formatics, we can scan the underlying DNA sequence of repetitive elements and other
FAIRE-positive regions of stem cells, looking for both the canonical and motifs mim-
icking that of the parental transcription factor. The bioinformatics predictions would
then be validated using lentiviral transduction of fusion proteins in MSCs and perform-
ing ChIP-seq. Ultimately, the results from these experiments would demonstrate that
the chromatin environment of stem cells is permissive for a range of fusion protein
retargeting, suggesting that the chromatin environment of stem cells is associated
with sarcoma development.
Interestingly, at sites where EWSR1-FLI1 is bound, cancer cells demonstrated an
increase in FAIRE signal relative to BM-MSCs. This suggests that binding of EWSR1-
FLI1 is increasing chromatin accessibility at these regions. However, neither EWSR1
or FLI1 have been associated with chromatin modifying activity, leading us to hy-
pothesize that EWSR1-FLI1 is cooperating with other proteins to remodel chromatin.
The simplest technique to assay partners of EWSR1-FLI1 would be to perform an
immunoprecipitation and use mass spectrometry to identify potential protein interac-
tions. Though theoretically simple, we and others have failed to co-purify EWRS1-
FLI1, suggesting that the protein is inherently unstable. An alternative approach is
to fuse EWSR1-FLI1 with a biotin ligase that biotynilates proximal and interacting
proteins [217]. Using this method, we could directly pull down proximal/interacting
partners of EWSR1-FLI1 using streptavidin and submit these results for mass spec-
trometry, looking for potential chromatin modifiers. Currently, our lab is using a novel
high-throughput screening approach to identify compounds that affect chromatin ac-
cessibility at EWSR1-FLI1 binding sites. Utilizing both approaches would be benefi-
cial as they are complimentary. The biotin assay would identify interacting partners
and the compound screen would identify those proteins that affected chromatin ac-
cessibility at EWSR1-FLI1 binding sites, narrowing the list of potential targets. The
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proteins from the intersecting set of these two approaches could lead to novel tar-
geted therapies for Ewing sarcoma.
Techniques using high-throughput sequencing are powerful for conducting both
discovery and hypothesis driven research. The sheer amount of information from
these experiments enables researchers to use the data for secondary projects. Though
we originally intended to identify regulatory regions in Ewing sarcoma cells, back-
ground signal from FAIRE-seq typically covers the remainder of the genome, allowing
a genome-wide sampling of DNA content. Unexpectedly, we identified an approxi-
mate 1 MB deletion encompassing the tumor suppressor PTEN. Until this study, the
consequences of PTEN loss had not yet been studied in Ewing sarcoma. Of the 7
Ewing sarcoma cell lines test, only EWS502 contained a PTEN loss validated by both
fluorescent in-situ hybridization and immunoblotting. However, we demonstrated that
25% (4/15) of patient tumors demonstrated loss of PTEN protein expression, a ratio
similar to that of and other previously described Ewing sarcoma recurrent mutations
CDKN2A (10%-30%)[198][199] and TP53 (3%-14%) [200][199].
Though, TP53 and CDKN2A have recently been implicated as prognostic biomark-
ers, large scale analysis of primary Ewing tumors revealed no significant difference
in event free survival for patients with these mutations [201]. Therefore, reliable
biomarkers remain to be identified. Loss of PTEN resulted in a significant increase in
activated AKT, leading to an enhancement of cellular transformative properties such
as increased proliferation and colony formation, as well as decreased apoptosis, re-
sults of consistent with other AKT activation studies [202][203][204]. The enhance-
ment of cellular transformative properties in PTEN null cells, suggests that patients
lacking PTEN may have more aggressive disease. However, to date, no studies have
associated PTEN status with clinical outcomes in Ewing sarcoma. The Children’s
Oncology Group, as well as many of our collaborators, have access to a significant
number of primary Ewing sarcoma tumors and corresponding clinical data. Using
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these resources, we could create a tissue microarray (TMA) of all available tumors.
Using IHC and analysis similar to our study, we would identify PTEN null tumors and
associate them with common clinical features such as time to relapse, disease free
survival, and incidence of metastasis looking for statistically significant differences
in PTEN null tumors. These studies would lend necessary evidence for PTEN as a
biomarker in Ewing sarcoma and serve to help stratify patients into risk categories.
Despite the preclinical success of IGF-1R inhibitors, they fail a significant fraction
of patients for unknown reasons [116][117][118]. Identifying these reasons, would
allow clinicians to tailor therapies based on predicted response, saving patients valu-
able time, and more importantly, preventing patients from experiencing debilitating
side effects from ineffective drugs. Our study demonstrated reciprocal responses to
IGF-1R and mTOR inhibition in PTEN null cells. Cells lacking PTEN have increased
levels of activated AKT even in the presence of potent IGF-1R inhibitors OSI-906
[137] and NVP-AEW541[205] (Figures 3.8 and 3.11). After exogenous expression of
PTEN, cells became more responsive to inhibitor treatments, suggesting that IGF-
1R-mediated inhibition of the AKT pathway requires functional PTEN. Our study also
noted a significant increase in response to mTOR inhibition in PTEN null cells. mTOR
a downstream target of AKT, is responsible for many cellular processes including au-
tophagy [206]. Inhibition of mTOR, in cells with PTEN loss, was associated with an
increase in autophagy and a concomitant decrease in cell viability consistent with
studies in other cell lines [207] including cancer cells [150][151]. Taken together, our
preclinical results suggest that patients with PTEN loss may not respond to IGF-R1
inhibitors. Alternatively, PTEN null patients may be more sensitive to therapies target-
ing PI3K, mTOR, and/or other downstream IGF-1R effectors. To test this idea, patient
tumors, whose PTEN status has been identified, would be cultured in-vitro and sub-
jected to various inhibitor treatments [208]. Similar to our study, therapies that reduce
activated AKT and cell viability would be identified as potential treatment options. The
78
results of these experiments could be brought to the clinic and may predict the most
effective therapies and treatment combinations for individual patient tumors.
Though, our experiments suggest that PTEN plays a crucial role in response to
therapies, these studies were all done using in-vitro cell culture. In order to prove
useful in a clinical setting it is essential that we demonstrate similar results in-vivo.
Despite not having a faithful mouse model of Ewing sarcoma, our lab has previously
demonstrated successful tumor formation using Ewing sarcoma cell lines in immun-
odeficient mice (unpublished data). To assay PTEN function with tumor progres-
sion and therapeutic response, CRISPR or lentiviral transduction of a doxycycline
inducible PTEN would be engineered in EWS502 cells. The cells would then be
injected into mice where tumor formation would occur. Our results suggest the ex-
pression of PTEN in this cell line is sufficient to prevent soft-agar formation, though
a second study contradicts this finding [209]. This contradiction may be due to dif-
fering levels of PTEN protein. Niemeyer et al. used an antibiotic selection method,
enriching for cells that could tolerate PTEN expression. It is possible that low levels
of PTEN may lower activated AKT, yet still allow for anchorage-independent growth,
while higher levels of PTEN cause apoptosis seen in our study. Controlled induction of
PTEN at various time points in an in-vivo system would help resolve the controversy.
We hypothesize that if expression of PTEN prevents tumor formation by increasing
apoptosis, early induction should prevent tumor formation, while late induction should
result in significant decrease of tumor size. Our results also suggest that PTEN ex-
pression enhances sensitivity to IGF-R1 inhibition while loss increases sensitivity to
mTOR inhibition. Using the inducible system described above, we could allow tu-
mor formation and induce PTEN expression while simultaneously treating with IGF-
1R/mTOR inhibitors. We hypothesize that the group expressing PTEN and treated
with inhibitor should have significantly decreased tumor size relative to both untreated
and PTEN expression alone with the reciprocal results for mTOR inhibitors. Determin-
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ing if PTEN expression modulates responsiveness to IGF-1R inhibtiors in-vivo, is an
important step before moving into a clinical setting. Preclinical and early-phase clin-
ical trials utilizing dual IGF-1R and mTOR inhibitors have begun to promising results
[152][153][154][155]. However our study suggests that these therapeutic strategies
may improve patient outcomes if stratified by PTEN status.
The preceding research has made scientific advances considered both transla-
tional and basic. Our results have suggested a potential mechanism for IGF-1R fail-
ure, as well as an alternative treatment in a subset of patients. Our study is one ex-
ample demonstrating how loss of regulatory proteins can ultimately lead to attenuated
drug sensitivity. Future studies should compare the genotypes of those patients who
respond and compare them to those who the therapy fails. Our results suggest that
informative insights into biology can be gained from those patients whose treatments
fail them. Ultimately, the majority of the patients suffering from Ewing sarcoma are
children, and the side effects from these therapies can be debilitating. Therefore, pre-
scribing treatments with increased predicted response is vital for patient well-being. In
addition, our study described a unique chromatin environment in stem cells that can
be exploited by cancer. Taken together, our results suggest an intriguing hypothesis
that stem cells can become cancerous. This impacts many facets of biology including
regeneration and tissue repair, where stem cells are being manipulated and used as
potential treatments. The recent discovery a stem cell specific chromatin remodeler
lends further evidence for unique biological factors defining stemness [218]. If the
chromatin environment is primed for oncogenic retargeting, it is not a far stretch to
think that other biological factors may also be permissive for oncogenesis. Together,
these studies have furthered our knowledge regarding therapy and the etiology of
Ewing sarcoma. Though much work is still needed, we are on the cusp of identify-
ing novel targeted therapeutics which have implications for patients who desperately
need improved therapies.
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